Search is not available for this dataset
Therapeutic
stringlengths 8
15
| Format
stringlengths 3
52
| CH1 Isotype
stringclasses 15
values | VD LC
stringclasses 9
values | Highest_Clin_Trial (Oct '21)
stringclasses 12
values | Est. Status
stringclasses 4
values | Heavy Sequence
stringlengths 2
132
| Light Sequence
stringlengths 2
113
| Heavy Sequence (if bispec)
stringlengths 2
132
| Light Sequence (if bispec)
stringlengths 2
112
| 100% SI Structure
stringlengths 7
224
⌀ | 99% SI Structure
stringlengths 7
364
⌀ | 95-98% SI Structure
stringlengths 7
207
⌀ | Year Proposed
int64 1.99k
2.02k
| Year Recommended
stringclasses 30
values | Target
stringlengths 2
75
| Companies
stringlengths 2
1.7k
| Conditions Approved
stringlengths 2
277
| Conditions Active
stringlengths 2
910
| Conditions Discontinued
stringlengths 2
384
⌀ | Development Tech
stringlengths 2
149
| Notes
stringlengths 8
194
⌀ | Heavy Sequence second
stringlengths 127
158
⌀ | Light Sequence second
stringlengths 116
136
⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lintuzumab | Whole mAb Radiolabelled | G1 | Kappa | Phase-II | Discontinued | QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYNMHWVRQAPGQGLEWIGYIYPYNGGTGYNQKFKSKATITADESTNTAYMELSSLRSEDTAVYYCARGRPAMDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASESVDNYGISFMNWFQQKPGKAPKLLIYAASNQGSGVPSRFSGSGSGTDFTLTISSLQPDDFATYYCQQSKEVPWTFGQGTKVEIK | na | na | null | null | null | 1,996 | 1997 | CD33 | PDL BioPharma;Seattle Genetics | na | na | Acute myeloid leukaemia;Myelodysplastic syndromes | na | null | Q VQLVQ SGA EVK KPGS SVKVSCK ASGY TFT DYN MHWVRQ APGQG LEWIGYIYP YNGGTGYNQK FKSKATITA DESTN TAYMELS SLRSEDT AVYYCA RGRPAMDYWGQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCRA SESVDNY GISFMN W F QQKPGKAP KLLIYAA SNQGSGVPS R FSGSGSGTD FTLTISS LQPDD FA TYYC QQSKEVPW T FGQGT KVEI K |
Linvoseltamab | Bispecific mAb | G4;G4 | Kappa | Phase-II | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFWMTWVRQAPGKGLEWVANMNQDGSEKYYVDSVKGRFTISRDNAKSSLYLQMNSLRAEDTAVYYCARDREYCISTSCYDDFDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK | EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYSMHWVRQAPGKGLEWVSGISWNSGSKGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKYGSGYGKFYHYGLDVWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK | None;None | None;None | None;None | 2,022 | na | TNFRSF17 | Regeneron Pharmaceuticals | na | Multiple Myeloma | na | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF TF SN FWMTWVR QAPGKG LEWVANM NQDGS EKYYVD SVKG RFTIS RDNAKS SLYLQMN SLRAEDT AVYYC ARDRE YCIST SCYDDFDYWGQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASQS ISSYLNWYQ QKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQP EDFA TYYC QQSYSTPP ITF GQGT RLEI K |
Lipustobart | Whole mAb | G4 | Kappa | TBC | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWMGGVNPSNGGTNFNEKFKSRVTITADKSTSTAYMELSSLRSEDTAVYYCARRDYRYDMGFDYWGQGTTVTVSS | EIVLTQSPATLSLSPGERATISCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYLESGVPARFSGSGSGTDFTLTISSLEPEDFATYYCQHSRELPLTFGTGTKVEIK | na | na | null | null | null | 2,022 | na | PDCD1 | TBC | TBC | TBC | TBC | TBC | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYYMYWVRQ APGQG LEWMG G V NPSNGGTNFNEKFK SRVTITA DKSTS TAYMELSS LRSEDT AVYYCAR RDYR Y DMG FDY WGQG TTVTVS S | E IVLT QSPA TLSL SPGE RATISCR ASKGVSTSGY SYLHWY QQKPGQAP RLLIY LASYL ESGVP ARFS GSGSGTD FTLTIS SLE PEDFATY YC QHSRELPL TF GTGT KVEI K |
Lirentelimab | Whole mAb | G1 | Kappa | Phase-III | Active | EVQLVESGGGLVQPGGSLRLSCAASGFSLTIYGAHWVRQAPGKGLEWVGVIWAGGSTNYNSALMSRFTISKDNSKNTVYLQMNSLRAEDTAVYYCARDGSSPYYYSMEYWGQGTTVTVSS | EIVLTQSPATLSLSPGERATLSCSATSSVSYMHWFQQKPGQAPRLLIYSTSNLASGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSSYPFTFGPGTKLDIK | na | na | null | null | null | 2,020 | 2021 | SIGLEC8 | Allakos | na | Eosinophilic gastroenteritis;Eosinophilic oesophagitis;Urticari;Atopic dermatitis;Chronic obstructive pulmonary disease | Conjunctiviti;Fibrosis;Kertoconjunctivitis;Systemic mastocytosis | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF SLTIYGAHWVRQ APGKGL EWVGVIWA GGSTNYNSA LMSRFTIS KDNSKN TVYLQMNS LRAEDT AVYYCA RDGSSP YYYSMEYW GQGT TVTVS S | E IVLTQ SPA TLSL SPGE RATLSCS ATSS VSYMHWF QQKPGQAP RLLIYS TSNLASGIP ARFS GSGSGT DFTLTIS SLEPED FAVYYCQ QRSSYPF TF GPGT KLD IK |
Lirilumab | Whole mAb | G4 | Kappa | Phase-II | Active | QVQLVQSGAEVKKPGSSVKVSCKASGGTFSFYAISWVRQAPGQGLEWMGGFIPIFGAANYAQKFQGRVTITADESTSTAYMELSSLRSDDTAVYYCARIPSGSYYYDYDMDVWGQGTTVTVSS | EIVLTQSPVTLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWMYTFGQGTKLEIK | na | na | null | null | null | 2,012 | 2013 | KIRD2 | Novo Nordisk;Bristol-Myers Squibb;Dana-Farber Cancer Institute;Innate Pharma;National Cancer Institute (USA);Ono Pharmaceutical;PrECOG;University of Texas M. D. Anderson Cancer Center | na | Chronic lymphocytic leukaemia;Head and neck cancer;Myelodysplastic syndromes;Solid tumours;Bladder cancer | Acute myeloid leukaemia;Hepatitis C;Haematological malignancies;Multiple myeloma;Lymphoma | Medarex UltiMAb Mouse | null | Q VQLVQ SGA EVK KPGS SVKVSCK ASGGT FSFYAISWVR QAPGQGL EWMGGFIPIF GAANYAQKFQG RVTITA DESTS TAYMELSS LRSDDT AVYYCAR IPSGS YYYD YDMD V WGQG TTVTVS S | E IVLT QSP VTLSL SPGE RATLSCR ASQS VSSY LAWY QQKPGQAP RLLIYD ASNRATG I P ARF SGSGSGTD FTLTIS SLEPED FAVYYCQ QRSN WMYTF GQGT KLEI K |
Litifilimab | Whole mAb | G1 | Kappa | Phase-III | Active | DVQLVESGGGLVKPGGSLRLSCAASGFTFSTYTMSWVRQAPGKGLEWVATISPGDSFGYYYPDSVQGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCTRDIYYNYGAWFAYWGQGTLVTVSS | DIQLTQSPSSLSASVGDRVTITCKASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASTLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANEDPRTFGQGTKVEIK | na | na | null | null | null | 2,022 | na | CLEC4C | Biogen Idec | na | Systemic lupus erythematosus;Cutaneous lupus erythematosus | na | na | null | D VQLVES GGG LV KPGG SLRLSC AASGF TFSTYTMSWVR QAPGKG LEWVATI SPGDS FGYY YPDSVQ GRFTIS RDNAKN SLYLQMNS LRAEDT AVYYCT RDI YY NYG AWFAYW GQG TLVTVS S | DI QLT QSPSS LSA SVGD RVTITCK ASQS V DYDGD SYMNWYQ QKPGKAP KLLIYAA STLESGVPS R FSGSGSGTD FTLTIS SLQPE DFA TYYCQ QANEDPRTFGQGT KVEI K |
Livmoniplimab | Whole mAb | G4 | Kappa | Phase-I | Active | QVQLVQPGAEVRKPGASVKVSCKASGYRFTSYYIDWVRQAPGQGLEWMGRIDPEDAGTKYAQKFQGRVTMTADTSTSTVYVELSSLRSEDTAVYYCARYEWETVVVGDLMYEYEYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCQASQSISSYLAWYQQKPGQAPKILIYGASRLKTGVPSRFSGSGSGTSFTLTISSLEPEDAATYYCQQYASVPVTFGQGTKVEIK | na | na | null | null | null | 2,021 | 2022 | LRRC32 | AbbVie | na | Solid tumours | na | na | null | Q VQLV QPGA EVR KPGA SVKVSCK ASGY RFTSYYIDWVR QAPGQG LEWMGR IDP ED AGTK YAQK FQG RVTMTA DTSTS TVYVELS SLRSEDT AVYYCAR YE WETVVV GD LMYEYEYW GQG TLVTVS S | DIQMTQSPSS LSA SVGD RVTITCQ ASQS ISSYLAWYQ QKPGQAP KILIYG ASRLKTGVPSRFSGSGSGT SFTLTIS SLE PEDAATYYCQQ YASVP VTF GQGT KVEI K |
Lodapolimab | Whole mAb | G1 | Lambda | Phase-I | Discontinued | QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARSPDYSPYYYYGMDVWGQGTTVTVSS | QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCQSYDSSLSGSVFGGGIKLTVL | na | na | null | null | null | 2,019 | 2020 | PDL1 | Dana-Farber Cancer Institute;Eli Lilly | na | na | Solid tumours | na | null | Q VQLVQ SGA EVK KPGS SVKVSCK ASGGT FSSYAISWVR QAPGQGL EWMGGIIPIF GTANYAQKFQG RVTITA DKSTS TAYMELS SLRSEDT AVYYCA RSPDYSP YYYYGMDV WGQG TTVTVS S | QSVLTQPPSASGTPGQ RVTISC SGSSSNIGSN TVNWYQQ LPGTAP KLLIY GNSNRPSGVPDRFSGSKSGT SASLAI SGLQSED EADY YCQ SYDSSLSGS VF GGG IKLTV L |
Lodelcizumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | QVQLVQSGAEVKKPGASVKVSCKASGYTFSTMYMSWVRQAPGQGLEWMGRIDPANEHTNYAQKFQGRVTMTRDTSISTAYMELSRLTSDDTAVYYCARSYYYYNMDYWGQGTLVTVSS | QIVLTQSPATLSVSPGERATLSCRASQSVSYMHWYQQKPGQAPRLLIYGVFRRATGIPDRFSGSGSGTDFTLTIGRLEPEDFAVYYCLQWSSDPPTFGQGTKLEIK | na | na | null | null | null | 2,012 | 2013 | PCSK9 | Novartis | na | na | Hypercholesterolaemia | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFSTMYMSWVR QAPGQG LEWMGRI DPANEHTNY A Q KF QG RVTMT RDTS ISTAYMELS RLTSDDT AVYYCA RS YYYY NMDYWGQG TLVTV SS | Q IVLTQ SPA TLSV SPGE RATLSCR ASQS VSYMHWYQ QKPGQAP RLLIYGVFRR ATGIPDRFSGSGSGT DFTLTIGR LEPED FAVYYCLQW SSDPPTFGQG TKLEI K |
Lokivetmab | Canine Whole mAb | G2 | Kappa | Approved | NFD | EVQLVESGGDLVKPGGSLRLSCVASGFTFSNYGMSWVRQAPGKGLQWVATISYGGSYTYYPDNIKGRFTISRDNAKNTLYLQMNSLRAEDTAMYYCVRGYGYDTMDYWGQGTLVTVSS | EIVMTQSPASLSLSQEEKVTITCKASQSVSFAGTGLMHWYQQKPGQAPKLLIYRASNLEAGVPSRFSGSGSGTDFSFTISSLEPEDVAVYYCQQSREYPWTFGQGTKLEIK | na | na | null | null | null | 2,014 | 2015 | IL31 | Zoetis | Canine atopic dermatitis | na | na | na | null | E VQLVE SGGD LV KPGG SLRLSCVA SGF TF SNYG MSWVRQ APGKG LQWVATIS YGGS YTY YPDNIK GRFTISR DNAKN TLYLQMN SLRAEDT AMYYCVR GYGYDTMDYWGQG TLVTVS S | E IVMT QSPA SLS LSQEE KVTITCK ASQ SVSF AGTG LMHWYQ QKPGQAP KLLIYRA SNLEAGVPSRFSGSGSGTD FSFTIS SLEPED VAVYYCQ QSREYPW T FGQGT KLEI K |
Lomtegovimab | Whole mAb | G1 | Kappa | Phase-II/III | Active | QVQLVESGGGVVQPGRSLRLSCAATGFTFRRYGMHWVRQAPGKGLEWVAGILFDGSNKYYVDSVKGRFTISRDSSRNTLYLQLNSLRREDTAVYYCAKGGDYEWELLESWGQGTLVTVSS | DIQMTQSPSTVSASVGDRVTITCRASQSIDNWLAWYQEKPGKAPKVLIYKASSLESGVPSRFSGRGSGTEFTLTISSLQPGDFATYYCQHYHSFPLTFGGGTKVDIK | na | na | null | null | null | 2,021 | 2022 | SARS-CoV-2 Spike RBD | Boehringer Ingelheim | na | COVID-19 | na | na | (June '22: Corrected VH sequence) | Q VQLVES GGG VV QPGR SLRLSC AATG FTFRRY G MHWVRQ APGKGL EWVAGILF DGSNK YYVD SVKG RFTISR DSSRN TLYLQLN SLRREDT AVYYCA KGGDY EWELLES WGQG TLVTVS S | DIQ MT QSPS TVSAS VGD RVTITCR ASQS IDNWLAW Y QEKPGKAP KVLIYKA SSLESGVPS RF SGRGSGT EFTLTISS LQPGD FATYYCQ HYHSFP LTF GGGT KVDI K |
Lomvastomig | Bispecific mAb with Domain Crossover | G1;G1 | Kappa;Kappa | TBC | Active | EVQLLESGGGLVQPGGSLRLSCAASGFSFSSYTMSWVRQAPGKGLEWVATISGGGRDIYYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVLLTGRVYFALDSWGQGTLVTVSS | DIVMTQSPDSLAVSLGERATINCKASESVDTSDNSFIHWYQQKPGQSPKLLIYRSSTLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNYDVPWTFGQGTKVEIK | EVQLVESGGGLVQPGGSLRLSCAASGFNIKTTYMHWVRQAPGKGLEWVGRIDPADDNTKYAPKFQGKATISADTSKNTAYLQMNSLRAEDTAVYYCVRDFGYVAWFAYWGQGTLVTVSS | DIVMTQSPLSLPVTPGEPASISCRASQSVDNYVAWYLQKPGQSPQLLIYYASNRYIGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQHYSSPYTFGQGTKVEIK | None;None | None;None | None;None | 2,022 | na | PDCD1;HAVCR2 | TBC | TBC | TBC | TBC | Humanised | null | E VQLLES GGG LV QPGG SLRLSCA ASGF SF S SYTMSWVR QAPGKG LEWVATIS GGGRD IY YPDSVK GRFTISR DNSKN TLYLQMNS LRAEDT AVYYCVLL TGR VYFALD SWGQG TLVTVS S | D IVMT QSPDS LAVS LGER ATINCK ASESVDTSDNS FIHWYQ QKPGQSP KLLIYR SSTLESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYCQ QNYDVPW TF GQGT KVEI K |
Loncastuximab | Whole mAb ADC | G1 | Kappa | Approved | Active | QVQLVQPGAEVVKPGASVKLSCKTSGYTFTSNWMHWVKQAPGQGLEWIGEIDPSDSYTNYNQNFQGKAKLTVDKSTSTAYMEVSSLRSDDTAVYYCARGSNPYYYAMDYWGQGTSVTVSS | EIVLTQSPAIMSASPGERVTMTCSASSGVNYMHWYQQKPGTSPRRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEPEDAATYYCHQRGSYTFGGGTKLEIK | na | na | null | 6ani:HL:IM | null | 2,017 | 2018 | CD19 | ADC Therapeutics | Diffuse large B cell lymphoma | Follicular lymphoma;Mantle-cell lymphoma;Non-Hodgkin's lymphoma | Precursor B-cell lymphoblastic leukaemia-lymphoma | na | null | Q VQLV QPGA EVV KPGA SVKLSC KTSG YTFT SN WMHWVK QAPGQGL EWIGEI DPSDSYTNYNQNFQG KAKLTVD KSTS TAYMEVSSL RSDDT AVYYCA RGSNP YYYAMD YWGQGT SVTVS S | E IVLT QSP AIMS ASPGE RVTMTCS ASSGVN YMHWYQ QKPGTSPR RWIYD TSKLASGVP ARFS GSGSGT SYSLTISS MEPEDAA TYYCH QRGS YTF GGG TKLEI K |
Lonigutamab | Whole mAb | G1 | Kappa | Phase-I/II | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYIHWVRQAPGQGLEWMGWIWPGDGSTKYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYFCASPMITPNYAMDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDISKYLNWYQQKPGKAPKLLIYYTSRLQSGVPSRFSGRGSGTDYSLTISSLQPEDFATYFCQQGSTLPYTFGGGTKVEIK | na | na | null | null | null | 2,020 | 2021 | IGF1R | Pierre Fabre | na | Solid tumours | na | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYYIHWVR QAPGQG LEWMGWIW PGDGSTK YAQKF QG RVTMTR DTSTS TVYMELS SLRSEDT AVYFCA SPMITPNYA M DYWGQG TLVTV SS | DIQ MT QSPSS LSA SVGD RVTITCR ASQD ISKYLNWYQ QKPGKAP KLLIYYT SRLQSGVPS RF SGRGSGTD YSLTIS SLQ PEDFATY F C QQGSTLP YT FGGGT KVEI K |
Lorigerlimab | Bispecific Mixed scFv (scFv-CH2-CH3-scFv) | G4;G4 | Kappa;Kappa | Phase-I/II | Active | QVQLVQSGAEVKKPGASVKVSCKASGYSFTSYWMNWVRQAPGQGLEWIGVIHPSDSETWLDQKFKDRVTITVDKSTSTAYMELSSLRSEDTAVYYCAREHYGTSPFAYWGQGTLVTVSS | EIVLTQSPATLSLSPGERATLSCRASESVDNYGMSFMNWFQQKPGQPPKLLIHAASNQGSGVPSRFSGSGSGTDFTLTISSLEPEDFAVYFCQQSKEVPYTFGGGTKVEIK | QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGSNKHYADSVKGRFTVSRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK | None;None | None;None | None;5xj3:AB/5tru:HL/6jc2:HL/6rp8:hl/7elx:HL:hl | 2,021 | 2022 | PDCD1;CTLA4 | MacroGenics | na | Solid tumours | na | Dual-Affinity Re-Targeting Technology | (June '22: Corrected VL sequences) | Q VQLVQ SGA EVK KPGA SVKVSCK ASGYS FTSYWMNWVR QAPGQGL EWIGVI HPSDSET WL DQKFKD RVTITVD KSTS TAYMELS SLRSEDT AVYYCAR EHYGTSPF AYW GQG TLVTVS S | E IVLTQ SPA TLSL SPGE RATLSCRA SESVDNYGM SFMN W F QQKPGQPP KLLIHA ASNQGSGVPS R FSGSGSGTD FTLTIS SLEPED FAVYFC QQSKEVP YT FGGG TKVEI K |
Lorukafusp | Whole mAb Fusion | G1 | Kappa | Phase-II | Active | EVQLVQSGAEVEKPGASVKISCKASGSSFTGYNMNWVRQNIGKSLEWIGAIDPYYGGTSYNQKFKGRATLTVDKSTSTAYMHLKSLRSEDTAVYYCVSGMEYWGQGTSVTVSS | DVVMTQTPLSLPVTPGEPASISCRSSQSLVHRNGNTYLHWYLQKPGQSPKLLIHKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPPLTFGAGTKLELK | na | na | null | null | 4tuj:CD:AB/4tul:HL/4trp:HL/4tuo:CD:AB/4tuk:HL | 2,018 | 2019 | Ganglioside GD2 | Lexigen Pharmaceuticals;Apeiron Biologics;Merck KGaA;University of Wisconsin-Madison | na | Malignant melanoma;Neuroblastoma | na | na | null | E VQLVQ SGA EVE KPGA SVKISCK ASGSSFTGYN MNW VR Q NIGKS LEWIGAI DPYYGGTSYNQKFKG RATLTVD KSTS TAYMHLKS LRSEDT AVYYCV SGM EY WGQG TSVTVS S | DV VMT QTPLSLPVTPGEPA SISC RSSQ SLVHR NGN TYLHWYLQ KPGQSP KLLIHKV SNRFSGVPDRFSGSGSGT DFTLKISRVE AEDL GVYFCS QSTHVPPL TF GAGT KLEL K |
Lorvotuzumab | Whole mAb ADC | G1 | Kappa | Phase-II | Discontinued | QVQLVESGGGVVQPGRSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAYISSGSFTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARMRKGYAMDYWGQGTLVTVSS | DVVMTQSPLSLPVTLGQPASISCRSSQIIIHSDGNTYLEWFQQRPGQSPRRLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPHTFGQGTKVEIK | na | na | null | null | null | 2,010 | 2011 | NCAM1 | ImmunoGen | na | na | Multiple myeloma;Solid tumours;Small cell lung cancer;Haematological malignancies | na | null | Q VQLVES GGG VV QPGR SLRLSC AASGF TFSS F GMHWVRQ APGKG LEWVAYIS SGS FTIYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCAR MRKG YAMD YWGQG TLVTVS S | DV VMT QSPLSLPV T LGQP ASISC RSS QIIIH SDGN TYLEWFQ QRPGQSPR RLIYKVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCF QGSHVPHTFGQG TKVEI K |
Losatuxizumab | Whole mAb ADC | G1 | Kappa | Phase-I | Discontinued | EVQLQESGPGLVKPSQTLSLTCTVSGYSISRDFAWNWIRQPPGKGLEWMGYISYNGNTRYQPSLKSRITISRDTSKNQFFLKLNSVTAADTATYYCVTASRGFPYWGQGTLVTVSS | DIQMTQSPSSMSVSVGDRVTITCHSSQDINSNIGWLQQKPGKSFKGLIYHGTNLDDGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCVQYAQFPWTFGGGTKLEIK | na | na | null | null | null | 2,016 | 2017 | EGFR | AbbVie | na | Solid tumours | na | na | Losatuxizumab and Serclutamab have identical variable domains | E VQLQE SGPGLVKPSQ TLSLTCTV SG YSI SRD FAWNWIR QPPGKGL EWMGYISY NGNTRYQPSLK SRITISR DTSKN QFFLKLN S V TAADTA TYYCVTA SRGFPYWGQ GTLVTVS S | DIQ MT QSPSS MSVS VGD RVTITCH SSQDINSN IGWLQ QKPGKS FKGLIYH GTNLDDGVPS RF SGSGSGTD YTLTISS LQPEDF ATYYCVQYA QFPWTFGGGT KLEI K |
Lucatumumab | Whole mAb | G1 | Kappa | Phase-I | Discontinued | QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYEESNRYHADSVKGRFTISRDNSKITLYLQMNSLRTEDTAVYYCARDGGIAAPGPDYWGQGTLVTVSS | DIVMTQSPLSLTVTPGEPASISCRSSQSLLYSNGYNYLDWYLQKPGQSPQVLISLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQARQTPFTFGPGTKVDIR | na | na | null | null | null | 2,007 | 2008 | CD40 | Novartis;XOMA | na | na | Chronic lymphocytic leukaemia;Follicular lymphoma;Lymphoma;Multiple myeloma | na | null | Q VQLVES GGG VV QPGR SLRLSC AASGF TFSS Y GMHWVRQ APGKG LEWVAVISY EESNR Y HADSV KGRFTIS RDNS KITLYLQM NSLRTEDT AVYYCA RDGG I AAPGPDYWGQG TLVTV SS | D IVMT QSPL SLTV TPGEP ASISCR SSQ SLLY SNGYN YLDWYL QKPGQSP QVLISL GSNRASGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCMQ ARQTPF TF GPGT KVD IR |
Lulizumab | Single Domain Variable Fragment;L | na | Kappa | Phase-II | Active | na | DIQMTQSPSSLSASVGDRVTITCRASRPIWPFLEWYQQKPGKAPKLLIYFTSRLRHGVPSRFSGSGSGTCFTLTISSLQPEDFATYYCLQNVANPATFSQGTKVEIK | na | na | null | null | null | 2,014 | 2015 | CD28 | Bristol-Myers Squibb | na | Sjogren's syndrome;Systemic lupus erythematosus;Renal transplant rejection | na | na | null | null | DIQ M TQSPSS LSA SVGD RVTITCR ASRPI WPFLEWYQ QKPGKAP KLLIYFT SRLRHGVPSRFSGSGSGT CFTLTIS SLQPEDF ATYYCLQ NVANPATFSQGT KVEI K |
Lumiliximab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | EVQLVESGGGLAKPGGSLRLSCAASGFRFTFNNYYMDWVRQAPGQGLEWVSRISSSGDPTWYADSVKGRFTISRENANNTLFLQMNSLRAEDTAVYYCASLTTGSDSWGQGVLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDIRYYLNWYQQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTEFTLTVSSLQPEDFATYYCLQVYSTPRTFGQGTKVEIK | na | na | null | 3fzu:HL:CD | null | 2,004 | 2004 | FCER2 | Biogen Idec | na | na | Allergic asthma;Allergic rhinitis;Chronic lymphocytic leukaemia | na | Lumiliximab and Gomiliximab are the same mAb | E VQLVES GGGLAKPGG SLRLSC AASG FRFTF NNY YMDWVR QAPGQG LEWVSRI SSSGDPT WYA DSVKG RFTISR ENANN TLFLQMN SLRAEDT AVYYCASLT TGSDSWGQ GVLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASQD IR YYLN W Y QQKPGKAP KLLIYVA SSLQSGVPS RF SGSGSGT EFTLTVSS LQPEDFA TYYCLQVYS TPRTFGQGT KVEI K |
Lumretuzumab | Whole mAb | G1 | Kappa | Phase-I/II | Discontinued | QVQLVQSGAEVKKPGASVKVSCKASGYTFRSSYISWVRQAPGQGLEWMGWIYAGTGSPSYNQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARHRDYYSNSLTYWGQGTLVTVSS | DIVMTQSPDSLAVSLGERATINCKSSQSVLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQSDYSYPYTFGQGTKLEIK | na | na | 4leo:AB | null | null | 2,014 | 2015 | ERBB3 | Roche | na | na | Breast cancer;Solid tumours;Non-small cell lung cancer | GlycoMAb Technology | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFRSSYISWVR QAPGQGL EWMGWIYA GTGSPSYNQK LQGRVTMTT DTSTS TAYMELRSL RSDDT AVYYCA RHRDYYSNS LTYW GQG TLVTVS S | D IVMT QSPDS LAVS LGER ATINC KSSQS VL NSGNQKN YLTWYQ QKPGQPP KLLIYWAS TRESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYC QSDYSYPY T FGQGT KLEI K |
Lunaxafusp | Fusion Protein | na | Kappa | TBC | Active | QVQLQQSGPELKKPGETVKISCKASGYPFTNYGMNWVKQAPGQGLKWMGWINTSTGESTFADDFKGRFDFSLETSANTAYLQINNLKSEDSATYFCARWEVYHGYVPYWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCKASQDVYNAVAWYQQKPGQSPKLLIYSASSRYTGVPSRFTGSGSGPDFTFTISSVQAEDLAVYFCQQHFRTPFTFGSGTKLEIK | na | na | null | null | null | 2,022 | na | ERBB2 | TBC | TBC | TBC | TBC | TBC | Murine scFv against a human antigen | QV QLQQ SGPELKKPGE TVKISCK ASGYPFTNY GMNWVK QAPGQG LKWMGWIN TSTGES TF ADDFKG RFDFSLET SANT AYLQIN NLKSEDSA TYFCARWEVYH G Y VPYWGQG TTVTVS S | DIQ MT QSPSS LSA SVGD RVTITCK ASQD VYNA VAWYQ QKPGQSP KLLIYS ASSRYTGVPSRFTGSGSGPD FTFTISS VQ AEDLA VYF CQ QHFRTPF TF GSGT KLEI K |
Lupartumab | Whole mAb ADC | G1 | Lambda | Phase-I | Discontinued | EVQLLESGGGLVQPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREGLWAFDYWGQGTLVTVSS | ESVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYVVHWYQQLPGTAPKLLIYDNNKRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDRLNGPVFGGGTKLTVL | na | na | null | null | null | 2,016 | 2017 | LYPD3 | Bayer HealthCare | na | na | Solid tumours | na | null | E VQLLES GGG LV QPGG SLRLSC AASGF TF SNA WMSWVR QAPGKGL EWVSYIS SSGS TIYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA REGL WAFDY WGQG TLVTVS S | ESVLTQPPSVSGAPGQ RVTISCT GSSSNIGAG YVVHW YQQ LPGTAP KLLIY DNNKRPSGVPDRFSGSKSGTS ASL A I SGLRSEDEAD YYCAAW DDRLNGP V FGGGT KLTV L |
Lusvertikimab | Whole mAb | G4 | Kappa | Phase-II | Active | QVQLVESGGGLVKPGGSLRLSCAVSGFTLSDYYMAWIRQAPGKGLEWVSTISASGLRTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARPLSAHYGFNYFDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRTSEDIYQGLAWYQQKPGKAPKLLLYSANTLHIGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQYYDYPLAFGGGTKVEIK | na | na | null | null | null | 2,020 | 2021 | IL7R | OSE Immunotherapeutics | na | Autoimmune diseases | na | na | null | Q VQLVES GGG LV KPGG SLRLSCAV SGF T LS DY YMAWIR QAPGKGL EWVSTIS ASGL RTY YPDSVKG RFTISR DNAKNS LYLQMNS LRAEDT AVYYCA RPLSAHYGFN YFD YWGQG TLVTV SS | DIQ MT QSPSS LSA SVGD RVTITCR TS EDIYQGLAWYQ QKPGKAP KLLLYS AN TLHIGV PSRFSGSGSGTD YTLTIS SLQ PEDFATYYCQQ YYDYPL AF GGG TKVEI K |
Lutikizumab | Bispecific Dual Variable Domain IG | G1;G1 | Kappa;Kappa | Phase-II | Discontinued | EVQLVESGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHGGAGTYYPDSVKGRFTISRDNSKNTLFLQMDSLRPEDTGVYFCARGGVTKGYFDVWGQGTPVTVSS | DIQMTQSPSSLSASVGDRVTITCRASGNIHNYLTWYQQTPGKAPKLLIYNAKTLADGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQHFWSIPYTFGQGTKLQIT | QVQLVESGGGVVQPGRSLRLSCTASGFTFSMFGVHWVRQAPGKGLEWVAAVSYDGSNKYYAESVKGRFTISRDNSKNILFLQMDSLRLEDTAVYYCARGRPKVVIPAPLAHWGQGTLVTFSS | DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYEASNLETGVPSRFSGSGSGSDFTLTISSLQPEDFATYYCQQTSSFLLSFGGGTKVEHK | None;None | None;None | None;None | 2,016 | 2017 | IL1A;IL1B | Abbott Laboratories;AbbVie | na | na | Osteoarthritis | Dual Variable Domain Immunoglobulin Technology | null | E VQLVES GGG VV QPGR SLRLSC SASG FIFSR YDM SWVR QAPGKGL EWVAYIS HGGAGT Y YPDSVK GRFTISR DNSKN TLFLQM DSLRPEDT GVYFCA RGG VTKGYFDVW GQGT PVTVS S | DI QMT QSPSS LSA SVGD RVTITCR ASGNI HNYLTWYQ QTPGKAP KLLIYN AK T LADGVPS RF SGSGSGTD YTFTIS SLQ PEDIATY Y C QH FWS IPY T FGQGT KLQI T |
Luveltamab | Whole mAb ADC | G1 | Kappa | TBC | Active | EVQLVESGGGLVQPGGSLRLSCAASGFNIRTQSIHWVRQAPGKGLEWIGDIFPIDGITDYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARGSWSWPSGMDYYLDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK | na | na | null | null | null | 2,022 | na | FOLR1 | TBC | TBC | TBC | TBC | TBC | null | E VQLVES GGG LV QPGG SLRLSC AASGF NIRTQSIHWVRQ APGKGL EWIGDIF PIDGITDYADSVKG RFTISA DTSKN TAYLQMN SLRAEDT AVYYCA RGS W SWPSGMD YYLDY WGQG TLVTV SS | DIQ MT QSPSS LSA SVGD RVTITCR ASQD VNTA VAWYQ QKPGKAP KLLIYSASFLY SGVPSRFSGSRSGTD FTLTIS SLQP EDFAT YYCQ QHYTTPPTFGQGT KVEI K |
Maftivimab | Whole mAb | G1 | Kappa | Preregistration | Discontinued | EVQLVESGGGLVQPGGSLRLSCAASGFTSSSYAMNWVRQAPGKGLEWVSTISGMGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKRGYPHSFDIWGQGTMVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQSISSFLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLTFGQGTRLEIK | na | na | null | null | null | 2,018 | 2019 | Zaire Ebolavirus GP | Regeneron Pharmaceuticals | na | na | Ebola virus infections | na | null | E VQLVES GGG LV QPGG SLRLSCA ASGFTSS SYAMNW VR QAPGKGL EWVSTI SGMGGS TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAE DTAVYYCAK RGYPH SFDIW GQG TMVTVS S | DIQ M TQSPSS LSA SVGD RVTITCR ASQS ISSFLNWYQ QKPGKAP KLLIYAA SSLQSGVPSRFSGSGSGTD FTLTIS SLQP EDFA TYYC QQSYS TLTF GQGT RLEI K |
Magrolimab | Whole mAb | G4 | Kappa | Phase-III | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYNMHWVRQAPGQRLEWMGTIYPGNDDTSYNQKFKDRVTITADTSASTAYMELSSLRSEDTAVYYCARGGYRAMDYWGQGTLVTVSS | DIVMTQSPLSLPVTPGEPASISCRSSQSIVYSNGNTYLGWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPYTFGQGTKLEIK | na | na | null | 5iwl:AA:BB | null | 2,018 | 2019 | CD47 | Forty Seven;Merck KGaA;Stanford University | na | Diffuse large B cell lymphoma;Follicular lymphoma;Non-Hodgkin's lymphoma;Colorectal cancer;Solid tumours;Acute myeloid leukaemia;Myelodysplastic syndromes;Ovarian cancer | Lymphoma | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTN Y NMHWVR QAPGQ RLEWMGTI YPGNDDTSYNQKFKD RVTITA DTSAS TAYMELS SLRSEDT AVYYC ARGG YRAMD YWGQG TLVTVS S | DI VMT QSPLSLPVTPGEPA SISC RSSQ SIVYS NGN TYLGWYLQ KPGQSP QLLIYKVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCF QGSHVP YT FGQGT KLEI K |
Manelimab | Whole mAb | G1 | Lambda | Phase-I | Discontinued | EVQLVESGGGVVRPGGSLRLSCAASGFTFDDYAMSWVRQAPGKGLEWVSDISWSGSNTNYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYHCARAPLLLAMTFGVGSWGQGTLVTVSS | QTVVTQEPSLSVSPGGTVTLTCGLSSGTVTAINYPGWYQQTPGQAPRTLIYNTNTRHSGVPDRFSGSISGNKAALTITGAQAEDEADYYCALYMGNGGHMFGGGTKLTVL | na | na | null | null | null | 2,019 | 2020 | PDL1 | Biocad | na | Solid tumours;Cancer | na | na | null | E VQLVES GG GVV RPGG SLRLSC AASGFT F DDY AMSWVR QAPGKGL EWVSDISW SGSNTNYADSVK GRFTISR DNAKN SLYLQMN SLRAEDT ALYHC ARAP LLLAMTF GVGSWGQG TLVTV SS | QT VVT QEP SLSV SPGG TVTLTC GLSSG TVTAIN YPGW Y QQTPGQAP RTLIYN TNTRHSGVPDRF S G SI SGNK AALTIT GAQAEDEAD YYCALYM GNGGHMFGGGT KLTV L |
Manfidokimab | Whole mAb | G4 | Kappa | Phase-I | Active | QVQLVQSGAEVVKPGASVKVSCKTSGYTFTEYTIHWVRQAPGQSLEWIGGINPNNGGTVYNQKFQGKVTLTVDKSTSTAYMELSSLRSEDTAVYYCARVRRGMDYWGQGTSVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDVTTAVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSVQPEDLATYYCQQHYSAPWTFGGGTNLEIK | na | na | null | null | null | 2,021 | 2022 | IL4R | Akeso Biopharma | na | Atopic dermatitis | na | na | null | Q VQLVQ SGA EVV KPGA SVKVSC KTSGY TFTEYTIHWVR QAPGQ SLEWIGGI NPNNGG TVYN QK F QG KVTLTVD KSTS TAYMELSS LRSEDT AVYYCARVR RGMDYWGQG TSVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASQDV TTAVAWYQ QKPGKAP KLLIYSASYRY TGVPSRFSGSGSGTD FTLTISS VQ PEDLATYYCQ QHYSAPW T FGGGT NLEI K |
Margetuximab | Whole mAb | G1 | Kappa | Approved | Active | QVQLQQSGPELVKPGASLKLSCTASGFNIKDTYIHWVKQRPEQGLEWIGRIYPTNGYTRYDPKFQDKATITADTSSNTAYLQVSRLTSEDTAVYYCSRWGGDGFYAMDYWGQGASVTVSS | DIVMTQSHKFMSTSVGDRVSITCKASQDVNTAVAWYQQKPGHSPKLLIYSASFRYTGVPDRFTGSRSGTDFTFTISSVQAEDLAVYYCQQHYTTPPTFGGGTKVEIK | na | na | null | null | null | 2,013 | 2014 | ERBB2 | Raven biotechnologies;GC Pharma;Green Cross;MacroGenics;Merck Sharp & Dohme | Breast cancer | Gastric cancer;Oesophageal cancer | Bladder cancer;Non-small cell lung cancer;Ovarian cancer;Haematological malignancies;Solid tumours | na | null | QV QLQQ SGPE LV KPGA SLKLSCT ASGFNIKD TYIHWVK QRPEQGL EWIGRIY PTNGY TRY DPKFQDK ATITA DTSSN TAYLQVSR LTSEDT AVYYCSR WGGDG FYAMD YWGQGA SVTVS S | D IVMTQ SH KFMS TSVGD RVSITCK ASQDVN TAVAWYQ QKPGHSP KLLIYSASFRY TGVPDRFTGSRSGT DFTFTISSV QAED LAVYYCQ QHYTTPPTFGGG TKVEI K |
Marstacimab | Whole mAb | G1 | Lambda | Phase-III | Active | EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAILGATSLSAFDIWGQGTMVTVSS | QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSGVFGGGTKLTVL | na | na | null | null | null | 2,013 | 2014 | ERBB2 | Pfizer | na | Haemophilia | na | na | null | E VQLLES GGG LV QPGG SLRLSC AASGF TFSSYAMSWVR QAPGKGL EWVSAIS GSGGS TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCAI LGATSL SAFDI WGQG TMVTV SS | QSVLTQPPSVSGAPGQ RVTISCT GSSSNIGAG YDVHWYQ QLPGTAP KLLIYG NSNRPSGVPDRFSGSKSGTS A SLAIT GLQAEDEAD YYCQS YDSSLSGSGVFGGGT KLTV L |
Masavibart | Whole mAb | G1 | Lambda | Approved | Active | QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYAMYWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRTEDTAVYYCASGSDYGDYLLVYWGQGTLVTVSS | QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQSEDEADYYCNSLTSISTWVFGGGTKLTVL | na | na | 6xdg:CA | null | null | 2,020 | 2021 | SARS-CoV-2 Spike RBD | Regeneron Pharmaceuticals | COVID-19 | na | na | na | Imdevimab is former name for Masavibart | Q VQLVES GGG VV QPGR SLRLSC AASGF TF SN YAMYWVRQ APGKG LEWVAVISY DGSNK YYAD SVKG RFTISR DNSKN TLYLQMN SLRTEDT AVYYC ASGSDYGD YLLVYW GQG TLVTVS S | QSALTQPA SV SGSPGQ SITISCT GTSSDVGG YNYVSWY Q QHPGKAP KLMIYD VSKRPSGVSNRFSGSKSGN TASLTIS GLQSED EADYYC NSLT SISTWVF GGGT KLTV L |
Matuzumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | QVQLVQSGAEVKKPGASVKVSCKASGYTFTSHWMHWVRQAPGQGLEWIGEFNPSNGRTNYNEKFKSKATMTVDTSTNTAYMELSSLRSEDTAVYYCASRDYDYDGRYFDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCSASSSVTYMYWYQQKPGKAPKLLIYDTSNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSHIFTFGQGTKVEIK | na | na | 3c08:HL/5vr9:HL:AB | 5vsi:HL/3c09:HL:CB | null | 2,003 | 2003 | EGFR | ImClone Systems;Merck KGaA;Takeda | na | na | Cervical cancer;Colorectal cancer;Gastric cancer;Head and neck cancer;Non-small cell lung cancer;Ovarian cancer | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSHWMHWVR QAPGQG LEWIGEF NPSNGRTNYNEKFKS KATMTVD TSTN TAYMELSS LRSEDT AVYYCAS RDYDYDGR YFDY WGQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCS ASSS VTYMYWYQ QKPGKAP KLLIYD TSNLASGVPS R FSGSGSGT DYTFTIS SLQ PEDIATYYC QQWSS HIFTF GQGT KVEI K |
Mavrilimumab | Whole mAb | G4 | Lambda | Phase-II | Active | QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELSIHWVRQAPGKGLEWMGGFDPEENEIVYAQRFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCAIVGSFSPLTLGLWGQGTMVTVSS | QSVLTQPPSVSGAPGQRVTISCTGSGSNIGAPYDVSWYQQLPGTAPKLLIYHNNKRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCATVEAGLSGSVFGGGTKLTVL | na | na | null | null | null | 2,009 | 2010 | CSF2RA | Zenyth Therapeutics Kiniksa Pharmaceuticals;MedImmune | na | Giant cell arteritis;COVID-19;Inflammation | Rheumatoid arthritis | CAT Phage Display | null | Q VQLVQ SGA EVK KPGA SVKVSCKV SGY TLTELSIHWVR QAPGKG LEWM GGFDPEEN EIVYAQRF QG RVTMT EDTSTDT AYMELSS LRSEDT AVYYCAIVG SFSPL TLGLW GQG TMVTVS S | QSVLTQPPSVSGAPGQ RVTISCT GSGSNIGAPYDV SWYQ QLPGTAP KLLIYH NNKRPSGVPDRFSGSKSGTS ASLAIT GLQAEDEAD YYCATVE AGLSGS VF GGGT KLTV L |
Mazorelvimab | Whole mAb | G1 | Kappa | Phase-I/II | Active | EVQLVESGGGLVQPGGSLILSCAASGFTFSGFAMSWVRQAPGKGLEWVATISSGGTYTYSPDSVMGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARRLRRNYYSMDYWGQGTMVTVSS | DIVMTQSPLSLPVTPGEPASISCKSTKSLLNSDGFTYLDWYLQKPGQSPQLLIYLVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQSNYLPFTFGGGTKVEIK | na | na | null | null | null | 2,021 | 2022 | Rabies Virus Spike Glycoprotein G | Synermore | na | Rabies post-exposure | na | na | null | E VQLVES GGG LV QPGG SLILSC AASGF TFSGFAMSWVR QAPGKG LEWVATIS SGG TYTY SPDSV MGRFTISR DNAKN SLYLQMN SLRAEDT AVYYCA RR LRRNY YSM DYWGQG TMVTVS S | DI VMT QSPLSLPVTPGEPA SISCK STK SLL NSDGF TYLDWYL QKPGQSP QLLIYLVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCF QSNYLP FTF GGG TKVEI K |
Mecbotamab | Whole mAb | G1 | Kappa | Phase-II | Active | EVQLVQSGAEVKKPGATVKISCKVSGYSFWGATMNWIRQPPGKGLEWIGLIKPSNGGTSYNQKFKGRVTISADKSISTAYLQWSSLKASDTAMYYCAHGHYESYEAMDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCKASQDVVSAVAWYQQKPGQAPRLLIYWQDTRHTGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQEHFSPPLTFGQGTKVEIK | na | na | null | null | null | 2,022 | na | AXL | BioAtla | na | Non-small cell lung cancer;Ovarian cancer;Soft tissue sarcoma;Solid tumours | na | na | null | E VQLVQ SGA EVK KPGA TVKISCKV SGY SFWGATMNWIR QPPGKGL EWIGLIK PSNGGTSYNQ KFKGRVTIS ADKS ISTAYLQWS SLKASDT AMYYC AHGH Y ES YEAM DYWGQG TLVTV SS | DI QMT QSPSS LSA SVGD RVTITCK ASQD VVSAVAWYQ QKPGQAP RLLIYWQ DTRHTGVPSRFSGSGSGT EFTLTISS LQPDDF ATYYC QEHFSPPL TF GQGT KVEI K |
Melredableukin | Whole mAb Fusion | G1 | Kappa | Phase-I | Active | EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGSGFDYWGQGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGQGTKVEIK | na | na | null | 6ghg:HL:AB | 5i1c:HL | 2,021 | 2022 | Non-Binding | Roche | na | Ulcerative colitis | na | na | Fused to IL2. (June '22: Corrected FWL3 sequence) | E VQLLES GGG LV QPGG SLRLSC AASGF TFSSYAMSWVR QAPGKGL EWVSAIS GSGGS TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA KGSGFDYWGQG TLVTVS S | E IVLTQ SPG TLSL SPGE RATLSCR ASQSVS SSY LAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEP EDF AVYYC QQ YGSSPL TF GQGT KVEI K |
Melrilimab | Whole mAb | G2 | Kappa | Phase-II | Discontinued | EVQLLESGGGLVQPGGSLRLSCAASGFTFSIYDMIWVRQAPGKGLEWVSSIRGEGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPWSTEGSFFVLDYWGQGTLVTVSS | EIVLTQSPATLSLSPGERATLSCRASQSVDDDLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQYITAPLTFGQGTKVEIK | na | na | null | null | null | 2,020 | 2021 | IL1RL1 | GlaxoSmithKline | na | na | Asthma;Atopic dermatitis | na | null | E VQLLES GGG LV QPGG SLRLSC AASGF TFSIYDMIWVRQ APGKG LEWVSSIR GEGGG TYYAD SVKG RFTISR DNSKN TLYLQMN SLRAED TAVYYCA RDPWSTEG SFFVLDY WGQG TLVTVS S | E IVLTQ SPA TLSL SPGE RATLSCRA SQSVDDD LA WYQ QKPGQAP RLLIYD ASNRATG I P ARF SGSGSGT DFTLTIS SLEPED FAVYYCQ Q YIT AP LT FGQGT KVEI K |
Metelimumab | Whole mAb | G4 | Kappa | Phase-II | Discontinued | EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKELEWVAVISYDGSIKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARTGEYSGYDTDPQYSWGQGTTVTVSS | EIVLTQSPSSLSASVGDRVTITCRASQGIGDDLGWYQQKPGKAPILLIYGTSTLQSGVPSRFSGSGSGTDFTLTINSLQPEDFATYYCLQDSNYPLTFGGGTRLEIK | na | na | 6amj:HL:BA/6amm:HL | 6anp:HL:BA | null | 2,003 | 2003 | TGFB1 | Cambridge Antibody Technology | na | na | Cancer;Fibrosis;Scleroderma | na | null | E VQLVES GGG VV QPGR SLRLSC AASGF TFSS Y GMHWVRQ APGKE LEWVAVIS YDGS IKYYAD SVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA RTGEYSGYDTDPQYSWGQG TTVTVS S | E IVLT QSPSS LSA SVGD RVTITCR ASQGIGDDLG WYQ QKPGKAP ILLIY GTSTLQSGVPSRFSGSGSGTD FTLTIN SLQPED F ATYYCL QDSNYP LTF GGG TRLEI K |
Mepolizumab | Whole mAb | G1 | Kappa | Approved | Active | QVTLRESGPALVKPTQTLTLTCTVSGFSLTSYSVHWVRQPPGKGLEWLGVIWASGGTDYNSALMSRLSISKDTSRNQVVLTMTNMDPVDTATYYCARDPPSSLLRLDYWGRGTPVTVSS | DIVMTQSPDSLAVSLGERATINCKSSQSLLNSGNQKNYLAWYQQKPGQPPKLLIYGASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNVHSFPFTFGGGTKLEIK | na | na | null | null | null | 1,999 | 2000 | IL5 | GlaxoSmithKline;McMaster University;National Institute of Allergy and Infectious Diseases | Asthma;Churg-Strauss syndrome;Hypereosinophilic syndrome | Chronic obstructive pulmonary disease;Hypereosinophilic syndrome;Nasal polyps;Eosinophilic oesophagitis | Atopic dermatitis | na | null | Q VTLRE SGPA LV KPTQ TLTLTCTV SGF SLTSYSVHWVR QPPGKGL EWLGVIWA SGGTDYN SAL MSRLSIS KDTSRN QVVLTMT NMDPVDT ATYYCA RDPPSS LLRLDY WGRGT PVTVS S | D IVMT QSPDS LAVS LGER ATINC KSS QSLL NSGNQ KNYLAWYQ QKPGQPP KLLIYG ASTRESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYC QNVHSFP FTF GGGT KLEI K |
Mevonlerbart | Whole mAb | G4 | Kappa | TBC | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGRGYNADYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKLEYFDYWGQGTLVTVSS | DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTDFTLTISSLRPEDFATYYCQQYNSYPLTFGGGTKVEIK | na | na | 5vyf:HL:BA | null | null | 2,022 | na | Fel d 1 | Regeneron | na | Cat allergies | na | Antigen: Felis silvestris catus (domestic cat) allergen 1 | null | E VQLVES GGG LV QPGG SLRLSC AASGF TFSSYAMSWVR QAPGKGL EWVSAI SGRGYNADYADSVK GRFTISR DNSKN TLYLQMN SLRAEDT AVYYCAKLEYF DYWGQG TLVTVS S | DIQMTQSPS TLSAS VGD RVTITCR ASQS ISSWLAWYQ QKPGKAP KLLIYK ASSLESGVPSRFSGSGSGTD FTLTIS SLR PEDFATYYCQQ YNSYP LTF GGGT KVEI K |
Mezagitamab | Whole mAb | G1 | Lambda | Phase-II | Active | EVQLLESGGGLVQPGGSLRLSCAASGFTFDDYGMSWVRQAPGKGLEWVSDISWNGGKTHYVDSVKGQFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGSLFHDSSGFYFGHWGQGTLVTVSS | QSVLTQPPSASGTPGQRVTISCSGSSSNIGDNYVSWYQQLPGTAPKLLIYRDSQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCQSYDSSLSGSVFGGGTKLTVL | na | na | null | null | null | 2,019 | 2020 | CD38 | Takeda | na | Multiple myeloma;Systemic lupus erythematosus;Idiopathic thrombocytopenic purpura;Myasthenia gravis | Rheumatoid arthritis | na | null | E VQLLES GGG LV QPGG SLRLSC AASGF TF DDYGM SWVRQ APGKGL EWVSDIS WNGGK THYVD SVKG QFTISR DNSKN TLYLQMN SLRAEDT AVYYC ARGS LFH DSSGF YF GHWGQG TLVTVS S | QSVLTQPPSASGTPGQ RVTISC SGSSSNIGD NYVSWYQQ LPGTAP KLLIYR DSQRPSGVPDRFSGSKSGTS ASLAI SGLRSEDE ADY YCQ SYDSSLSGS V FGGGT KLTV L |
Mibavademab | Whole mAb | G4 | Kappa | Phase-II | Active | QVQLVESGGSVVQPGRSLRLSCAASGFTFSTYAMYWVRQTPGKGLEWVAVLYSDGSNKYYIDSVKGRFTISRDTSTNTLYLQMSSLRADDSALYYCARLNWDYWYFDLWGRGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK | na | na | null | null | null | 2,020 | 2021 | LEPR | Regeneron Pharmaceuticals | na | Lipodystrophy | na | na | null | Q VQLVE SGG SVV QPGR SLRLSC AASGF TFSTYAMYWVRQ TPGKG LEWVAVLYS DGSN KYYID SVKG RFTISR DTSTN TLYLQMS SLRADDS ALYYCAR LNWD YWYFD LWGRG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASQS ISSYLNWYQ QKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQP EDFA TYYC QQSYSTPP ITF GQGT RLEI K |
Milatuzumab | Whole mAb | G1 | Kappa | Phase-I/II | Discontinued | QVQLQQSGSELKKPGASVKVSCKASGYTFTNYGVNWIKQAPGQGLQWMGWINPNTGEPTFDDDFKGRFAFSLDTSVSTAYLQISSLKADDTAVYFCSRSRGKNEAWFAYWGQGTLVTVSS | DIQLTQSPLSLPVTLGQPASISCRSSQSLVHRNGNTYLHWFQQRPGQSPRLLIYTVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSSHVPPTFGAGTRLEIK | na | na | null | null | null | 2,007 | 2008 | CD74 | Immunomedics | na | na | Graft-versus-host disease;Haematological malignancies;Chronic lymphocytic leukaemia;Multiple myeloma;Non-Hodgkin's lymphoma;Systemic lupus erythematosus | na | null | QV QLQQ SGS E LKKPGA SVKVSCK ASGY TFTNYGVNWIK QAPGQG LQWMGWI NPNTGEPTFDDDFKG RFAFSL DTSVS TAYLQISSL KADDT AVYFCS RSRGKNE AWFAYW GQG TLVTVS S | DI QLT QSPLSLPV T LGQPA SISC RSSQ SLVHR NGN TYLHWFQ QRPGQSP RLLIYTVS NRFSGVPDRFSGSGSGT DFTLKISRVE AED VGVYFCS QSSHVPPTFGAG TRLEI K |
Mipasetamab | Whole mAb | G1 | Kappa | Phase-I | Active | QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVATISSGGSYTYYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHPIYYTYDDTMDYWGQGTTVTVSS | EIVLTQSPGTLSLSPGERATLSCSASSSVSSGNFHWYQQKPGLAPRLLIYRTSNLASGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQWSGYPWTFGGGTKLEIK | na | na | null | null | null | 2,020 | 2021 | AXL | ADC Therapeutics | na | Solid tumours;Advanced or metastatic solid tumours | na | na | null | Q VQLVES GGG VV QPGR SLRLSC AASGF TFSS YG MSWVRQ APGKG LEWVATIS SGGS YTY YPDSVK GRFTISR DNSKN TLYLQMN SLRAEDT AVYYC ARHP IYYT YDDTMDYWGQG TTVTVS S | E IVLTQ SPG TLSL SPGE RATLSCS ASSSVSSGN FHWYQ QKPGLAP RLLIYRT SNLASGIP ARFS GSGSGT DFTLTISS LEPED FAVYYCQ QWSGYPW TF GGG TKLEI K |
Miptenalimab | Whole mAb | G4 | Kappa | Phase-II | Active | QVTLVESGGGVVQPGRSLRLSCAFSGFSLSTSDMGVGWIRQAPGKGLEWVAHIWWDDVKRYNPALKSRFTISRDNSKNTLYLQMNSLRAEDTAVYFCARIEDYGVSYYFDYWGQGTTVTVSS | DIQMTQSPSFLSASVGDRVSITCKASQDVSTAVAWYQQKPGKAPKLLIYSASYRYTGVPDRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYSIPLTFGQGTKLEIK | na | na | null | null | null | 2,019 | 2020 | LAG3 | Boehringer Ingelheim | na | Solid tumours;Head and neck cancer;Non-small cell lung cancer | na | na | null | Q VTLVES GGG VV QPGR SLRLSCAF SGF SLS TSDMG VGWIRQ APGKGL EWVAHIWW DDV K RYNPALK SRFTISR DNSKN TLYLQMNS LRAEDT AVYFCARI EDYG VSYYFD YWGQG TTVTVS S | DIQMTQSPS FLSA SVGD RVSITCK ASQD VSTA VAWY Q QKPGKAP KLLIYSASYRY TGVPDRFSGSGSGTD FTLTIS SLQ PEDFATYYC QQHYSIP LTF GQGT KLEI K |
Mirikizumab | Whole mAb | G4 | Kappa | Preregistration | Active | QVQLVQSGAEVKKPGSSVKVSCKASGYKFTRYVMHWVRQAPGQGLEWMGYINPYNDGTNYNEKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNWDTGLWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCKASDHILKFLTWYQQKPGKAPKLLIYGATSLETGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQMYWSTPFTFGGGTKVEIK | na | na | null | null | null | 2,017 | 2018 | IL23A | Eli Lilly | na | Plaque psoriasis;Ulcerative colitis;Crohn's disease | na | na | null | Q VQLVQ SGA EVK KPGS SVKVSCK ASGY KFTRYVMHWVR QAPGQG LEWMGYI NPYNDGTNYNEK F KG RVTITA DKSTS TAYMELS SLRSEDT AVYYCAR NWDTGLWGQG TTVTVS S | DIQ MT QSPSS LSA SVGD RVTITCK ASD HILKFLTWY QQKPGKAP KLLIYG ATSLETGVPSRFSGSGSGTD FTLTIS SLQ PEDFAT YYCQMY WSTPF T FGGGT KVEI K |
Miromavimab | Whole mAb (Mouse) | G1 | Kappa | Approved | NFD | QVQLQQPGSVLVRPGASVKLSCKTSGYAFTSSWMHWAKQRPGQGLEWIGQTHPNSGYTNYNEKFKGKATLTVDTSSSTAYVDLSSLTSEDSAVYYCARESGDGPHWYFDVWGAGTAVTVSS | DIVMTQSHKFMSTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYSASYRYTGVPDRFTGSGSGTDFTFTISSVQAEDLAVYYCQQHYSSPHTFGGGTKLETK | na | na | null | null | null | 2,019 | 2020 | Rabies Virus Strain ERA GP Ectodomain Epitope G-II | Candila Healthcare | Rabies | na | na | na | null | QV QL QQPG SVLV RPGA SVKLSC KTSGY AFT SS WMHWAK QRPGQGL EWIG QTHPNSGYTNYNEKFKG KATLTVD TSSS TAYVD LSSLTSEDS AVYYCAR ESGDGP HWYFDVW GAG TAVTVS S | D IVMTQ SH KFMS TSVGD RVSITCK ASQD VST AVAWYQ QKPGQSP KLLIYSASYRY TGVPDRFTGSGSGT DFTFTISS VQ A ED L AVYYCQ QHYSSPHTFGGGT KLE TK |
Mirvetuximab | Whole mAb ADC | G1 | Kappa | Preregistration | Active | QVQLVQSGAEVVKPGASVKISCKASGYTFTGYFMNWVKQSPGQSLEWIGRIHPYDGDTFYNQKFQGKATLTVDKSSNTAHMELLSLTSEDFAVYYCTRYDGSRAMDYWGQGTTVTVSS | DIVLTQSPLSLAVSLGQPAIISCKASQSVSFAGTSLMHWYHQKPGQQPRLLIYRASNLEAGVPDRFSGSGSKTDFTLTISPVEAEDAATYYCQQSREYPYTFGGGTKLEIK | na | na | null | null | null | 2,015 | 2016 | FOLR1 | ImmunoGen;National Comprehensive Cancer Network | na | Fallopian tube cancer;Ovarian cancer;Peritoneal cancer;Breast cancer;Endometrial cancer | Solid tumours | na | null | Q VQLVQ SGA EVV KPGA SVKISCK ASGY TFTGYFMNWVK QSPGQS LEWIGRI HPYDGDT FY NQK F QG KATLTVD KSSNT AHMELLSL TSED FAVYYCTR YDGSRA M D Y WGQG TTVTVS S | D IVLT QSPL SLAVS LGQP AIISC KASQS VSF AGT SLMHWYH QKPGQQP RLLIYR ASNLEAGVPDRFSGSGSKTD FTLTIS PVE AEDAATYYCQ QSREYPY T FGGGT KLEI K |
Mirzotamab | Whole mAb | G1 | Kappa | Phase-I | Discontinued | EVQLQESGPGLVKPSETLSLTCAVTGYSITSGYSWHWIRQFPGNGLEWMGYIHSSGSTNYNPSLKSRISISRDTSKNQFFLKLSSVTAADTAVYYCAGYDDYFEYWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCKASQNVGFNVAWYQQKPGKSPKALIYSASYRYSGVPSRFSGSGSGTDFTLTISSLQPEDFAEYFCQQYNWYPFTFGQGTKLEIK | na | na | null | null | null | 2,019 | 2020 | CD276 | AbbVie | na | na | Haematological malignancies;Solid tumours | na | null | E VQLQE SGPGL V KPSE TLSLTCAVT G YSI TSGY SWHWIRQ FPGNGL EWMGYIH SSGSTNYNPSLK SRISISR DTSKN QFFLKLS SVTAADT AVYYC AGYDDY FEYW GQG TTVTVS S | DI QMT QSPSS LSA SVGD RVTITCK ASQNV GFNVAWYQ QKPGKSPK ALIYSASYRY SGVPSRFSGSGSGTD FTLTIS SLQ PEDFAEYFCQQ YNWYPF T FGQGT KLEI K |
Mitazalimab | Whole mAb | G1 | Lambda | Phase-II | Active | EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWLSYISGGSSYIFYADSVRGRFTISRDNSENALYLQMNSLRAEDTAVYYCARILRGGSGMDLWGQGTLVTVSS | QSVLTQPPSASGTPGQRVTISCTGSSSNIGAGYNVYWYQQLPGTAPKLLIYGNINRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDKSISGLVFGGGTKLTVL | na | na | null | null | null | 2,017 | 2019 | CD40 | Alligator Bioscience;Janssen Biotech | na | Solid tumours | na | na | Mitazalimab is the new name for Vanalimab (PL119) | E VQLLES GGG LV QPGG SLRLSC AASGF TFST YG MHWVRQ APGKGL EWLSYI SGGS SYIFYA DSVRG RFTISR DNSEN ALYLQMN SLRAEDT AVYYCARILR GGSGMDL W GQG TLVTVS S | QSVLTQPPSASGTPGQ RVTISCT GSSSNIGAG YNVYWYQQ LPGTAP KLLIYG NINRPSGVPDRFSGSKSGTS ASLAI SGLRS E D EADYYCAAW DKSIS GLVF GGGT KLTV L |
Modakafusp | Whole mAb Fusion | G4 | Kappa | Phase-I/II | Active | EVQLVQSGAEVKKPGATVKISCKVSGYTFTDSVMNWVQQAPGKGLEWMGWIDPEYGRTDVAEKFQGRVTITADTSTDTAYMELSSLRSEDTAVYYCARTKYNSGYGFPYWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCKASQNVDSDVDWYQQKPGKAPKLLIYKASNDYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCMQSNTHPRTFGGGTKVEIK | na | na | null | null | null | 2,019 | 2020 | ADPRC | Takeda | na | Multiple myeloma | na | na | null | E VQLVQ SGA EVK KPGA TVKISCKV SG YTF TDS VMNW VQ QAPGKGL EWMGWI DPEYGRTD VAE KFQG RVTITA DTSTDT AYMELS SLRSEDT AVYYCAR TKYNSGYGFPYWGQG TTVTVS S | DI QMT QSPSS LSA SVGD RVTITCK ASQNVDSDVD WYQ QKPGKAP KLLIYK ASNDYTGVPSRFSGSGSGT DFTFTIS SLQPEDI ATYYCM QSNTHPRTFGGG TKVEI K |
Modotuximab | Whole mAb | G1 | Kappa | Phase-III | Active | QVQLQQPGAELVEPGGSVKLSCKASGYTFTSHWMHWVKQRPGQGLEWIGEINPSSGRNNYNEKFKSKATLTVDKSSSTAYMQFSSLTSEDSAVYYCVRYYGYDEAMDYWGQGTSVTVSS | DIVMTQAAFSNPVTLGTSASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLASGVPDRFSSSGSGTDFTLRISRVEAEDVGVYYCAQNLELPYTFGGGTKLEIK | na | na | null | null | null | 2,012 | 2014 | EGFR | Symphogen;Merck | na | Colorectal cancer;Glioma;Non-small cell lung cancer | Head and neck cancer;Oesophageal cancer | na | Modotuximab is the new name for Zatuximab (PL110) | QV QLQ QPGA ELV EPGG SVKLSCK ASGY TFTSHWMHWVK QRPGQGL EWIGEI NPSSGRNNYNEKFKS KATLTVD KSSST AYMQFS SLTSEDS AVYYCVRYY GYDEAMDYWGQG TSVTVS S | D IVMTQ AAFSNPV T LGTS ASISC RSSK SLLH SNG ITYLYWYLQ KPGQSP QLLIYQM SNLASGVPDR F SSSGSGT DFTLRISRVE AEDV GVYYCA QNLELPY T FGGG TKLEI K |
Mogamulizumab | Whole mAb | G1 | Kappa | Approved | Active | EVQLVESGGDLVQPGRSLRLSCAASGFIFSNYGMSWVRQAPGKGLEWVATISSASTYSYYPDSVKGRFTISRDNAKNSLYLQMNSLRVEDTALYYCGRHSDGNFAFGYWGQGTLVTVSS | DVLMTQSPLSLPVTPGEPASISCRSSRNIVHINGDTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSLLPWTFGQGTKVEIK | na | na | null | null | null | 2,010 | 2011 | CCR4 | Amgen;Bristol-Myers Squibb;Kagoshima University Dental School;Kyowa Hakko;Kyowa Hakko Kirin;Ono Pharmaceutical | Adult T-cell leukaemia-lymphoma;Cutaneous T-cell lymphoma;Peripheral T-cell lymphoma;Mycosis fungoides;Sezary syndrome;Mycosis fungoides | Spinal cord disorders | Non-small cell lung cancer;Asthma;Hypersensitivity;Solid tumours | POTELLIGENT Technology | null | E VQLVE SGGD LV QPGR SLRLSC AASG FIFS NYG MSWVRQ APGKG LEWVATIS SAST YSY YPDSVK GRFTISR DNAKNS LYLQMNSLRV EDT ALYYCGR HSDGN FAFGYW GQG TLVTVS S | DV LMT QSPLSLPVTPGEPA SISCR SSRN IVHI NGD TYLEWYL QKPGQSP QLLIYKVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCF QGS L LPW TF GQGT KVEI K |
Monalizumab | Whole mAb | G4 | Kappa | Phase-III | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMNWVRQAPGQGLEWMGRIDPYDSETHYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGGYDFDVGTLYWFFDVWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCRASENIYSYLAWYQQKPGKAPKLLIYNAKTLAEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYGTPRTFGGGTKVEIK | na | na | null | null | null | 2,015 | 2016 | KLRC1 | Innate Pharma;MedImmune;NCIC Clinical Trials Group;Novo Nordisk | na | Head and neck cancer;Non-small cell lung cancer;Cervical cancer;Chronic lymphocytic leukaemia;Endometrial cancer;Fallopian tube cancer;Ovarian cancer;Peritoneal cancer;Solid tumours;Haematological malignancies | Inflammation;Rheumatoid arthritis | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYWMNWVR QAPGQGL EWMGRI DPYDSETH YAQK LQG RVTMTT DTSTS TAYMELRSL RSDDT AVYYCA RGGY D FDVG TLYWFFDV WGQG TTVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASEN IYSY LAWY QQKPGKAP KLLIYN AKTLAEGVPSRFSGSGSGTD FTLTIS SLQP EDFAT YYCQ HHYGTPRTFGGG TKVEI K |
Mosunetuzumab | Bispecific mAb | G1 | Kappa;Kappa | Approved | Active | EVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYIHWVRQAPGQGLEWIGWIYPGDGNTKYNEKFKGRATLTADTSTSTAYLELSSLRSEDTAVYYCARDSYSNYYFDYWGQGTLVTVSS | DIVMTQSPDSLAVSLGERATINCKSSQSLLNSRTRKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCTQSFILRTFGQGTKVEIK | EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYNMHWVRQAPGKGLEWVGAIYPGNGDTSYNQKFKGRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARVVYYSNSYWYFDVWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASSSVSYMHWYQQKPGKAPKPLIYAPSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSFNPPTFGQGTKVEIK | None;None | None;None | None;4k7p:YX | 2,017 | 2018 | CD3E;MS4A1 | Genentech | na | Diffuse large B cell lymphoma;Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma;Follicular lymphoma | na | na | null | E VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTNYYIHWVRQ APGQG LEWIGWIY PGDGNTKYNEKFKG RATLTA DTSTS TAYLELS SLRSEDT AVYYCA RDSYSN YYFDY WGQG TLVTVS S | D IVMT QSPDS LAVS LGER ATINC KSSQ SLL NSRTR KNYLAWYQ QKPGQPP KLLIYWA STRESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYC TQ SFILRT FGQGT KVEI K |
Motavizumab | Whole mAb | G1 | Kappa | Phase-III | Discontinued | QVTLRESGPALVKPTQTLTLTCTFSGFSLSTAGMSVGWIRQPPGKALEWLADIWWDDKKHYNPSLKDRLTISKDTSKNQVVLKVTNMDPADTATYYCARDMIFNFYFDVWGQGTTVTVSS | DIQMTQSPSTLSASVGDRVTITCSASSRVGYMHWYQQKPGKAPKLLIYDTSKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCFQGSGYPFTFGGGTKVEIK | na | na | 3qwo:AB:HL/3ixt:HL:AB/4zyp:NO:JL:KM/6oe5:BC/6ywd:AB | 5k8a:BA:FE:VM:HL/4jlr:AB:HL | null | 2,006 | 2007 | RSV gpF | MedImmune | na | na | Respiratory syncytial virus infections | Affinity Matured from Palivizumab | null | Q VTLRE SGPA LV KPTQ TLTLTCTF SGF SL STAG MSVGWIR QPPGKA LEWLADIWW DDKKHYNPSLKD RLTISK DTSKN QVVLKVTN MDPADT ATYYCA RDM IFNFYFDV WGQG TTVTVS S | DI QMT QSPS TLSAS VGD RVTITCS ASSR VGYMHWYQ QKPGKAP KLLIYD TSKLASGVPS RF SGSGSGT EFTLTISS LQPDDF ATYYCF QGSGYP FTF GGG TKVEI K |
Moxetumomab | Fv Fusion | na | Kappa | Approved | NFD | EVQLVESGGGLVKPGGSLKLSCAASGFAFSIYDMSWVRQTPEKCLEWVAYISSGGGTTYYPDTVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCARHSGYGTHWGVLFAYWGQGTLVTVSA | DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSILHSGVPSRFSGSGSGTDYSLTISNLEQEDFATYFCQQGNTLPWTFGCGTKLEI | na | na | null | null | null | 2,009 | 2010 | CD22 | National Cancer Institute (USA);AstraZeneca;M. D. Anderson Cancer Center;MedImmune;National Cancer Institute (USA) | Hairy cell leukaemia | na | Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma;Precursor B-cell lymphoblastic leukaemia-lymphoma;Precursor cell lymphoblastic leukaemia-lymphoma | CAT Phage Display | null | E VQLVES GGG LV KPGG SLKLSC AASG FAFSIYD MS WV RQTPEKC LEWVAYIS SGGGT TY YPDTV KGRFTISR DNAKN TLYLQMS SLKSEDT AMYYCAR HSGYGTH WGVLFAYW GQG TLVTVS A | DIQ MTQ TTS SLSA SLGD RVTISCR ASQD ISNYLNWYQ QKPDGT VKLLIYYTSIL HSGVPSRFSGSGSGTD YSLTIS NLEQE DFATY FC QQGNTLPW TF GCGT KLE I |
Murlentamab | Whole mAb | G1 | Kappa | Phase-II | Active | QVRLVQSGAEVKKPGASVKVSCKASGYTFTSYHIHWVRQAPGQRLEWMGWIYPGDDSTKYSQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCTRGDRFAYWGQGTLVTVSS | DIQMTQSPSTLSASVGDRVTITCRASSSVRYIAWYQQKPGKAPKLLTYPTSSLKSGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCLQWSSYPWTFGGGTKVEIK | na | na | null | null | null | 2,018 | 2019 | AMHR2 | LFB Biotechnologies;GamaMabs Pharma | na | Colorectal cancer;Gynaecological cancer | na | na | null | Q VRLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYHIHWVR QAPGQ RLEWMGWIY PGDDSTKYS QKF QG RVTITR DTSAS TAYMELS SLRSEDT AVYYCT RGD RFAYW GQG TLVTVS S | DI QMT QSPS TLSAS VGD RVTITCR ASSS VRYIAWYQ QKPGKAPK LLT YPTSSLKSGVPS RF SGSGSGT EFTLTISS LQPDDF ATYYCLQW SSYPW TF GGG TKVEI K |
Mupadolimab | Whole mAb | G1 | Kappa | Phase-III | Active | QVQLVQSGAEVEKPGASVKVSCKASGYTFTSYWITWVRQAPGQGLEWMGDIYPGSGNTNYNEKFKTRVTITADKSTSTAYMELSSLRSEDTAVYYCAKEGGLTTEDYALDYWGQGTLVTVSS | EIVLTQSPATLSLSPGERATLSCRASKNVSTSGYSYMHWYQQKPGQAPRLLIYLASNLESGIPPRFSGSGYGTDFTLTINNIESEDAAYYFCQHSRELPFTFGQGTKVEIK | na | na | null | null | null | 2,021 | 2022 | NT5E | Corvus Pharmaceuticals | na | COVID-19 infections;Oropharyngeal cancer;Cancer | na | na | null | Q VQLVQ SGA EVE KPGA SVKVSCK ASGY TFTSYWITWVR QAPGQG LEWMGDI YPGSGNTNYNEKF KTRVTITA DKSTS TAYMELS SLRSEDT AVYYCAK EGGLTTED YALDY WGQG TLVTV SS | E IVLTQ SPA TLSL SPGE RATLSCRA SKNVSTSGY SYMHWYQ QKPGQAP RLLIYLA SNLESGIPPRFSGSGYGTD FTLTIN NIESEDA AYYFC QHSRELPF T FGQGT KVEI K |
Muromonab | Whole mAb | G2a | Kappa | Approved | Discontinued | QVQLQQSGAELARPGASVKMSCKASGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSS | QIVLTQSPAIMSASPGEKVTMTCSASSSVSYMNWYQQKSGTSPKRWIYDTSKLASGVPAHFRGSGSGTSYSLTISGMEAEDAATYYCQQWSSNPFTFGSGTKLEIN | na | na | 1sy6:HL | null | null | 1,988 | 1989 | CD3E | Cancer Research UK;Ortho-McNeil;XOMA | na | na | Diabetes mellitus;Graft-versus-host disease;Renal transplant rejection;Rheumatoid arthritis | na | LC IMGT 127 is N not K as in Jain paper. | QV QLQ QSGA EL ARPGA SVKMSCK ASGY TFTRYTMHWVK QRPGQG LEWIGYI NPSRGYTNYNQKFKDK ATLTT DKSSST AYMQLS SLTSEDS AVYYCARY YDDH YCLDY WGQG TTLTVS S | Q IVLT QSP AIMS ASPGE KVTMTCS ASSS VSYMN W YQ QKSGTSPK RWIYD TSKLASGVPA HFR GSGSGT SYSLTIS GME AEDAAT YYCQ QWSSNPF T FGSGT KLEI N |
Nadecnemab | Whole mAb | G4 | Kappa | Phase-II | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSVISGSGGSTYYADAVKGRFTISRDNSKHTLYLQMNSLRAEDTAVYYCTKPSSYSSSNFYYGMDVWGQGTTVTVSS | DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTNSFPFPFGPGTKVDIK | na | na | null | null | null | 2,020 | 2021 | GFRA3 | Regeneron Pharmaceuticals | na | Osteoarthritis;Pain chronic | na | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF TFSSYAMSWVR QAPGKGL EWVSVIS GSGGS TYYAD AVKG RFTISR DNSKH TLYLQMN SLRAED TAVYYCT KPSSYSSSN FYYGMDV WGQG TTVTVS S | DIQ MT QSPSS VSAS VGD RVTITCR ASQG ISSWLAWYQ QKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQ PEDFAT YYC QQTNSFPFPFGPGT KVDI K |
Nadunolimab | Whole mAb | G1 | Kappa | Phase-II | Active | QVQLVQSGAEVKKPGSSVKVSCKASGYAFTSSWMNWVRQAPGQGLEWMGRIYPGDGNTHYAQKFQGRVTLTADKSTSTAYMELSSLRSEDTAVYYCGEGYLDPMDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCQASQGINNYLNWYQQKPGKAPKLLIHYTSGLHAGVPSRFSGSGSGTDYTLTISSLEPEDVATYYCQQYSILPWTFGGGTKVEIK | na | na | null | null | null | 2,018 | 2019 | IL1RAP | Lund University;Cantargia | na | Non-small cell lung cancer;Pancreatic cancer;Solid tumours | na | na | Nadunolimab is the new name for Nidanilimab (PL122) | Q VQLVQ SGA EVK KPGS SVKVSCK ASGY AFT SSW MNWVR QAPGQG LEWMGRI YPGDGNT HYAQKF QG RVTLTA DKSTS TAYMELS SLRSEDT AVYYC GEGYLDPMDYWGQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCQ ASQG INNYLNWYQ QKPGKAP KLLIHY TSGLHAGVPSRFSGSGSGTD YTLTIS SLE PEDVATYYCQQ YSILPW T FGGGT KVEI K |
Namilumab | Whole mAb | G1 | Kappa | Phase-II | Active | QVQLVQSGAEVKKPGASVKVSCKAFGYPFTDYLLHWVRQAPGQGLEWVGWLNPYSGDTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCTRTTLISVYFDYWGQGTMVTVSS | DIQMTQSPSSVSASVGDRVTIACRASQNIRNILNWYQQRPGKAPQLLIYAASNLQSGVPSRFSGSGSGTDFTLTINSLQPEDFATYYCQQSYSMPRTFGGGTKLEIK | na | na | null | null | null | 2,010 | 2011 | CSF2 | Micromet Inc;Izana Bioscience;Takeda Pharmaceuticals International GmbH | na | Ankylosing spondylitis;COVID-19 | Plaque psoriasis;Rheumatoid arthritis | Human Phage Display | null | Q VQLVQ SGA EVK KPGA SVKVSCKA FGYPFT DY LLHWVR QAPGQGL EWVGWL NPYSGDTNY AQ KF QG RVTMT RDTS ISTAYMELS RLRSDDT AVYYC TRT TLISVYFD YWGQG TMVTVS S | DIQMTQSPSS VSA SVGD RVTIACR AS QNIRNILNWYQQ RPGKAP QLLIYA ASNLQSGVPSRFSGSGSGTD FTLTIN SLQ PEDFAT YYC QQSYSMPRTFGGGT KLEI K |
Naptumomab | Fab Fusion | G1 | Kappa | Phase-III | Discontinued | EVQLQQSGPDLVKPGASVKISCKASGYSFTGYYMHWVKQSPGKGLEWIGRINPNNGVTLYNQKFKDKATLTVDKSSTTAYMELRSLTSEDSAVYYCARSTMITNYVMDYWGQGTSVTVSS | SIVMTQTPTSLLVSAGDRVTITCKASQSVSNDVAWYQQKPGQSPKLLISYTSSRYAGVPDRFSGSGYGTDFTLTISSVQAEDAAVYFCQQDYNSPPTFGGGTKLEIK | na | na | null | null | null | 2,006 | 2007 | TPBG | Active Biotech | na | na | Non-small cell lung cancer;Pancreatic cancer;Renal cancer | na | null | EV QLQQ SGPDLVKPGA SVKISCK ASGY SFTGYYMHWVK QSPGKG LEWIGRI NPNNG VTLYN QKFKDK ATLTVD KSST TAYMELRS LTSEDS AVYYCA RST MITNYVMD YWGQGT SVTVS S | S IVMT QTPT SLLVS AGD RVTITCK ASQSVSND VAWYQ QKPGQSP KLLISYT SSRYAGVPDRFSGSGYGTD FTLTISSV QAEDA AVYFCQQ DYNSPPTFGGG TKLEI K |
Naratuximab | Whole mAb ADC | G1 | Kappa | Phase-II | Active | QVQVQESGPGLVAPSQTLSITCTVSGFSLTTSGVSWVRQPPGKGLEWLGVIWGDGSTNYHPSLKSRLSIKKDHSKSQVFLKLNSLTAADTATYYCAKGGYSLAHWGQGTLVTVSS | DIQMTQSPSSLSVSVGERVTITCRASENIRSNLAWYQQKPGKSPKLLVNVATNLADGVPSRFSGSGSGTDYSLKINSLQPEDFGTYYCQHYWGTTWTFGQGTKLEIK | na | na | null | null | null | 2,015 | 2016 | CD37 | ImmunoGen;Chronic lymphocytic leukaemia | na | Diffuse large B cell lymphoma;Non-Hodgkin's lymphoma | Chronic lymphocytic leukaemia | na | null | Q VQVQE SGPG LV APSQ TLSITCTV SG FSLTT SG VSWVR QPPGKGL EWLGVIW GDGSTNYHPSLKS RLSIK KDHSKS QVFLKL NSLT A AD T ATYYC AKGGY SLAH WGQG TLVTVS S | DI QMT QSPS SLSVS VGE RVTITCR ASENI R SN L AWYQ QKPGKSP KLLVNVAT NLADGVPS RF SGSGSGTD YSLKI NSLQPEDFGT YYCQHY WGT TWTF GQGT KLEI K |
Narlumosbart | Whole mAb | G4 | Kappa | TBC | Active | EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGITGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPGTTVIMSWFDPWGQGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVRGRYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVFYCQQYGSSPRTFGQGTKVEIK | na | na | null | null | null | 2,022 | na | TNFSF11 | TBC | TBC | TBC | TBC | TBC | 6ghg is technically within 95% ID, but CDRH3 length 7 vs length 15 | E VQLLES GGG LV QPGG SLRLSC AASGF TFSSYAMSWVR QAPGKG LEWVSGI TGSGGS TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAED TAVYYCA KDPGT TVIMSWF DPWGQ GTLVTVS S | E IVLTQ SPG TLSL SPGE RATLSCR ASQSVRG RYLAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEPED FAVFYCQ QYGSSPRTFGQGT KVEI K |
Narnatumab | Whole mAb | G1 | Kappa | Phase-I | Discontinued | EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYLMTWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLNLQMNSLRAEDTAVYYCTRDGYSSGRHYGMDVWGQGTTVIVSS | EIVLTQSPATLSLSPGERATLSCRASQSVSRYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPRTFGQGTKVEIK | na | na | null | null | null | 2,011 | 2012 | MST1R | ImClone Systems;Eli Lilly;ImClone Systems | na | na | Solid tumours | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF TFSSYLMTWVR QAPGKG LEWVANIK QDGS EKYYVD SVKG RFTIS RDNAKNS LNLQM N SL RAEDT AVYYCT RDGYSSGR HYGMDV WGQG TTVIVS S | E IVLT QSPA TLSL SPGE RATLSCR ASQS VSRYLAWY QQKPGQAP RLLIYD ASNRATGIP ARF SGSGSGTD FTLTIS SLEPED FAVYYCQ QRSNWPRTFGQGT KVEI K |
Narsoplimab | Whole mAb | G4 | Lambda | Preregistration | Active | QVTLKESGPVLVKPTETLTLTCTVSGFSLSRGKMGVSWIRQPPGKALEWLAHIFSSDEKSYRTSLKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIRRGGIDYWGQGTLVTVSS | QPVLTQPPSLSVSPGQTASITCSGEKLGDKYAYWYQQKPGQSPVLVMYQDKQRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTAVFGGGTKLTVL | na | na | null | null | null | 2,019 | 2020 | MASP2 | Omeros | na | Haemolytic uraemic syndrome;IgA nephropathy;Immediate hypersensitivity;Thrombotic microangiopathies;Glomerulonephritis;Lupus nephritis;Membranous glomerulonephritis | Stroke;Wet age-related macular degeneration | na | null | QV TLK ESGP VLV KPTE TLTLTCTVS G FS LSRG KMGVSWIR QPPGK ALEWLAHIF SSDEKS YRT SLK SRLTIS KDTSKN QVVLTMT NMDPVD TAT YYCARIR RGG I D Y WGQG TLVTV SS | QPVLTQPPS LSV SPGQ TASITC SGEKLGD KYAYWYQ QKPGQSP VLVMYQ DKQRPSGIPERFSGSNSGN TATLTIS GTQAMDEAD YYCQAW DSSTA VF GGGT KLTV L |
Natalizumab | Whole mAb | G4 | Kappa | Approved | Active | QVQLVQSGAEVKKPGASVKVSCKASGFNIKDTYIHWVRQAPGQRLEWMGRIDPANGYTKYDPKFQGRVTITADTSASTAYMELSSLRSEDTAVYYCAREGYYGNYGVYAMDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCKTSQDINKYMAWYQQTPGKAPRLLIHYTSALQPGIPSRFSGSGSGRDYTFTISSLQPEDIATYYCLQYDNLWTFGQGTKVEIK | na | na | null | 4irz:HL/6fg1:HL/6fg2:HL:IM | null | 1,998 | 1999 | ITGA4 | Biogen;Biogen Idec;Elan Corporation;Perrigo | Crohn's disease;Multiple sclerosis | Epilepsy;Graft-versus-host disease;Stroke | Multiple myeloma;Rheumatoid arthritis | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGFNIKD TYIHWVR QAPGQ RLEWMGRI DPANGY TKY DPKFQG RVTITA DTSAS TAYMELS SLRSEDT AVYYCA REGYYGN YGVYAMD YWGQG TLVTVS S | DIQMTQSPSS LSA SVGD RVTITCK TS QDINKYMAWYQ QTPGKAP RLLIHYT SALQPGIPSRFSGSGSGRD YTFTIS SLQ PEDIA TYYCLQ YDN LWTF GQGT KVEI K |
Navivumab | Whole mAb | G1 | Kappa | Preclinical | Discontinued | QVQLVQSGAEVKKPGASVKVSCKTSGYSFSTYGVSWVRQAPGQGPEWVGWISAYTGITDYAQKFQGRVTLTTDATTATAFLDLRSLRPDDTATYFCARDKVQGRVEVGSGGRHDYWGQGTLVIVSS | EVVLTQSPGTLALPPGERATLSCRASHRVGSTYIAWYQQKSGQAPRRLIYGASNRATDIPDRFSGSGSGTDFTLTIRRLEPEDSAVYYCQQFSVSPWTFGQGTRVEIK | na | na | 4r8w:HL/4ubd:CD:KL:YX:ST:OP:GH | 6fg1:HL/6fg2:HL | null | 2,015 | 2016 | Influenza A HA | Celltrion | na | na | Influenza A virus H1N1 subtype;Influenza A virus H5N1 subtype;Influenza virus infections | na | null | Q VQLVQ SGA EVK KPGA SVKVSC KTSGY SFSTYGVSWVR QAPGQGPE WVGWISAY TGITD YAQ KFQG RVTLTT DATTA TAFLD LRSLRPDDT ATYFCA RDKVQG RVEV GSGGRHDYWGQG TLVIVS S | E VVLTQ SPG TLA LPPGE RATLSCRAS HRVGS TYIAWYQ QKSGQAPR RLIYG ASNRATDIPDRFSGSGSGT DFTLTIRR LEPEDS AVYYCQQFSV SPWTFGQG TRVEI K |
Navicixizumab | Bispecific mAb | G2;G2 | Kappa;Kappa | Phase-I | Active | QVQLVQSGAEVKKPGASVKISCKASGYSFTAYYIHWVKQAPGQGLEWIGYISNYNRATNYNQKFKGRVTFTTDTSTSTAYMELRSLRSDDTAVYYCARDYDYDVGMDYWGQGTLVTVSS | DIVMTQSPDSLAVSLGERATISCRASESVDNYGISFMKWFQQKPGQPPKLLIYAASNQGSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEVPWTFGGGTKVEIK | QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWMHWVRQAPGQGLEWMGDINPSNGRTSYKEKFKRRVTLSVDKSSSTAYMELSSLRSEDTAVYFCTIHYDDKYYPLMDYWGQGTLVTVSS | DIVMTQSPDSLAVSLGERATISCRASESVDNYGISFMKWFQQKPGQPPKLLIYAASNQGSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEVPWTFGGGTKVEIK | None;None | None;None | None;None | 2,015 | 2016 | DLL4;VEGFA | OncoMed Pharmaceuticals | na | Fallopian tube cancer;Ovarian cancer;Peritoneal cancer | Colorectal cancer;Solid tumours | na | null | Q VQLVQ SGA EVK KPGA SVKISCK ASGY SFTAYYIHWVK QAPGQG LEWIGYIS NYNRATNYNQK FKGRVTFTT DTSTS TAYMELRSL RSDDT AVYYCAR DYDYDVGMDYWGQG TLVTVS S | D IVMT QSPDS LAVS LGER ATISCR ASESVDNYG ISFMK W F QQKPGQPP KLLIYAA SNQGSGVPDRFSGSGSGTD FTLTISS LQAED VAVYYC QQSKEVPW T FGGG TKVEI K |
Naxitamab | Whole mAb | G1 | Kappa | Approved | Active | QVQLVESGPGVVQPGRSLRISCAVSGFSVTNYGVHWVRQPPGKGLEWLGVIWAGGITNYNSAFMSRLTISKDNSKNTVYLQMNSLRAEDTAMYYCASRGGHYGYALDYWGQGTLVTVSS | EIVMTQTPATLSVSAGERVTITCKASQSVSNDVTWYQQKPGQAPRLLIYSASNRYSGVPARFSGSGYGTEFTFTISSVQSEDFAVYFCQQDYSSFGQGTKLEIK | na | na | null | null | null | 2,018 | 2019 | Ganglioside GD2 | Memorial Sloan-Kettering Cancer Center;Y-mAbs Therapeutics | Neuroblastoma | Osteosarcoma | Breast cancer;Sarcoma;Small cell lung cancer | na | null | Q VQLVE SGPG VV QPGR SLRISCAV SGF SVTNYGVHWVR QPPGKGL EWLGVIWA GGITNYNSA FMSRLTIS KDNSKN TVYLQMNS LRAEDT AMYYCA SRGGHY GYALDY WGQG TLVTVS S | E IVMT QTPA TLSVS AGE RVTITCK ASQSVSND VTWYQ QKPGQAP RLLIYS ASNRYSGVP ARF SGSGYGT EFTFTISS VQSED FAVYFCQ QDYSSFGQG TKLEI K |
Necitumumab | Whole mAb | G1 | Kappa | Approved | Active | QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYYWSWIRQPPGKGLEWIGYIYYSGSTDYNPSLKSRVTMSVDTSKNQFSLKVNSVTAADTAVYYCARVSIFGVGTFDYWGQGTLVTVSS | EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYGSTPLTFGGGTKAEIK | na | na | 6b3s:JK:CD:HL:FG/3b2u:WX:QR:TU:JK:CD:NO:FG:HL/3b2v:HL | null | null | 2,008 | 2009 | EGFR | ImClone Systems;Eli Lilly | Non-small cell lung cancer | Solid tumours | Colorectal cancer | na | null | Q VQLQE SGPGLVKPSQ TLSLTCTV SGGSISSGD YYWSWIR QPPGKGL EWIGYIYYS GSTDYNPSLK SRVTMSVD TSKN QFSLKVNSVT AADT AVYYCARVSIF GVG TFD YWGQG TLVTVS S | E IVMT QSPA TLSL SPGE RATLSCR ASQS VSSYL A W Y QQKPGQAP RLLIYD ASNRATGIP ARF SGSGSGTD FTLTIS SLEPE D FAVYYCH QYGSTPL TF GGGT KAEI K |
Nemolizumab | Whole mAb | G2 | Kappa | Approved | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYIMNWVRQAPGQGLEWMGLINPYNGGTDYNPQFQDRVTITADKSTSTAYMELSSLRSEDTAVYYCARDGYDDGPYTLETWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCQASEDIYSFVAWYQQKPGKAPKLLIYNAQTEAQGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYDSPLTFGGGTKVEIK | na | na | null | null | null | 2,014 | 2015 | IL31RA | Chugai Pharmaceutical;Galderma;Maruho | Atopic dermatitis | Prurigo nodularis;Pruritus;Scleroderma | na | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTGYIMNWVR QAPGQGL EWMGLI NPYNGGTDYNPQFQD RVTITA DKSTS TAYMELS SLRSEDT AVYYCA RDGYDDGP YTLETW GQG TLVTVS S | DI QMT QSPSS LSA SVGD RVTITCQ ASED IYSFVAWYQ QKPGKAP KLLIYN AQTEAQGVPS R FSGSGSGTD FTLTISS LQP EDFA TYYCQ HHYDSPL TF GGG TKVEI K |
Nepuvibart | Whole mAb | G1 | Kappa | Approved | NFD | QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYITYSGSTIYYADSVKGRFTISRDNAKSSLYLQMNSLRAEDTAVYYCARDRGTTMVPFDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCQASQDITNYLNWYQQKPGKAPKLLIYAASNLETGVPSRFSGSGSGTDFTFTISGLQPEDIATYYCQQYDNLPLTFGGGTKVEIK | na | na | 6xdg:BD | null | null | 2,020 | 2021 | SARS-CoV-2 Spike RBD | Regeneron Pharmaceuticals | COVID-19 | na | na | na | Casirivimab is the former name for Nepuvibart | Q VQLVES GGG LV KPGG SLRLSC AASGF TF SD YYMSWIR QAPGKGL EWVSYITY SGS TIYYA DSVKG RFTIS RDNAKS SLYLQMN SLRAEDT AVYYCA RDRGT TMV PFDYWGQG TLVTV SS | DIQ M TQSPSS LSA SVGD RVTITCQ AS QDITNYLNWYQ QKPGKAP KLLIYAA SNLETGVPSRFSGSGSGTD FTFTIS GLQ PEDIATYYCQQ YDNLP LTF GGGT KVEI K |
Nesvacumab | Whole mAb | G1 | Kappa | Phase-I | Discontinued | EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDIHWVRQATGKGLEWVSAIGPAGDTYYPGSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARGLITFGGLIAPFDYWGQGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSSTYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYDNSQTFGQGTKVEIK | na | na | null | null | null | 2,012 | 2013 | ANGPT2 | Regeneron Pharmaceuticals;Sanofi | na | na | Solid tumours | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF TFSSYDIHWVRQ ATGKG LEWVSAI GPAGDT Y YPGS VKGRFTIS RENAKN SLYLQMNS LRAGD TAVYYC ARG LITF GG LI APFDYWGQG TLVTV SS | E IVLTQ SPG TLSL SPGE RATLSCR ASQSVSS TYLAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEPED FAVYYCQH YDNSQTFGQG TKVEI K |
Netakimab | Whole mAb | G1 | Kappa | Approved | Active | QVQLVQSGGGLVQAGGSLRLSCAASGGTFATSPMGWLRQAPGKGTEFVAAISPSGGDRIYADSVKGRFTISRDNAGYFIYLQMNSLKPEDTAVYYCAVRRRFDGTSYYTGDYDSWGQGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYSYSPVTFGQGTKVEIK | na | na | null | null | null | 2,017 | 2018 | IL17A | CJSC Biocad | Plaque psoriasis | Ankylosing spondylitis;Psoriatic Arthritis;Primary biliary cirrhosis | na | na | null | Q VQLVQS GGG LVQ AGG SLRLSCA ASGGT FAT SPMG WLRQ APGKGT EFVAAI SPSGGD RIYAD SVKG RFTIS RDNAG YFIYLQM NSLKPEDT AVYYCAVRRR FDGT SYYTG DYDSWGQG TLVTVS S | E IVLTQ SPG TLSL SPGE RATLSCR ASQSVSSS YLAWYQ QKPGQAP RLLIYD ASSRATGIPDRFSGSGSGT DFTLTISR LEP ED FAVYYCQ QYSYSPV T FGQGT KVEI K |
Nimacimab | Whole mAb | G4 | Kappa | Phase-I | Active | QVQLVQSGAEVKKPGSSVKVSCKASGYEFSYYWMNWVRQAPGQGLEWMGQIYPGDGETKYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARSHGNYLPYWGQGTLVTVSS | EIVLTQSPATLSLSPGERATLSCRASQSVSSSYLHWYQQKPGQAPRLLIYSTSNLASGIPARFSGSGSGTDFTLTISRLEPEDFAVYYCHQYHRSPPTFGQGTKVEIK | na | na | null | null | null | 2,018 | 2019 | CNR1 | Bird Rock Bio | na | Diabetic nephropathies;Diabetic gastroparesis;Obesity | Non-alcoholic steatohepatitis;Non-alcoholic fatty liver disease | na | null | Q VQLVQ SGA EVK KPGS SVKVSCK ASGY EFSYYWMNWVR QAPGQG LEWMGQI YPGDGET KYAQKF QG RVTITA DKSTS TAYMELS SLRSEDT AVYYCAR SHGNYLPYWGQG TLVTVS S | E IVLTQ SPA TLSL SPGE RATLSCR ASQSVSSS YLHWYQ QKPGQAP RLLIYS TSNLASGIP ARFS GSGSGT DFTLTISR LEPED FAVYYCHQY HRSPPTFGQGT KVEI K |
Nimotuzumab | Whole mAb | G1 | Kappa | Approved | Active | QVQLQQSGAEVKKPGSSVKVSCKASGYTFTNYYIYWVRQAPGQGLEWIGGINPTSGGSNFNEKFKTRVTITADESSTTAYMELSSLRSEDTAFYFCTRQGLWFDSDGRGFDFWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCRSSQNIVHSNGNTYLDWYQQTPGKAPKLLIYKVSNRFSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCFQYSHVPWTFGQGTKLQIT | na | na | null | 3gkw:HL | null | 2,005 | 2006 | EGFR | Biocon Biopharmaceuticals;Biotech Pharmaceutical;Center of Molecular Immunology;CIMYM;Daiichi Sankyo Inc;Eurofarma;Gilead Sciences;Innogene Kalbiotech;InnoMab;Kuhnil Pharmaceutical Company;Laboratorios Pisa;Oncoscience | Anaplastic astrocytoma;Brain cancer;Glioblastoma;Glioma;Head and neck cancer;Nasopharyngeal cancer;Oesophageal cancer | Cervical cancer;Non-small cell lung cancer;Pancreatic cancer;Breast cancer;Colorectal cancer | Gastric cancer;Polycystic kidney disease;Prostrate cancer;Brain metastases;Squamous cell cancer | na | (Feb '22) Conflict between our sequence and IMGT-mAb/DB. We take the seminal paper as source of the sequence: https://cancerres.aacrjournals.org/content/69/14/5851. | Q VQLQQ SGA EVK KPGS SVKVSCK ASGY TFTNYYIYWVRQ APGQG LEWIGGI NPTSGGSNFNEKF KTRVTITA DESST TAYMELS SLRSEDT AFYFC TRQG LWF DSDGR GFDFW GQG TTVTVS S | DI QMT QSPSS LSA SVGD RVTITCR SSQN IVH SNGN TYLDWYQ QTPGKAP KLLIYKV SNRFSGVPS R FSGSGSGT DFTFTISS LQPEDI ATYYCFQY SHVPWTFGQGT KLQI T |
Nipocalimab | Whole mAb | G1 | Lambda | Phase-III | Active | EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGASGSQTRYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSS | QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMIYGDSERPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYAGSGIYVFGTGTKVTVL | na | na | null | null | 5whk:HL/5whj:HL | 2,019 | 2020 | FCGRT | Momenta | na | Autoimmune haemolytic anaemia;Haemolytic disease of newborn;Myasthenia gravis | na | na | null | E VQLLES GGG LV QPGG SLRLSC AASGF TFSTYAMGWVRQ APGKG LEWVSSI GASGSQ TRY ADSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCARLAI GDSYWGQG TMVTVS S | QSALTQPA SV SGSPGQ SITISC TGTGSDVG SY N LVSWYQ QHPGKAP KLMIY GDSERPSGVSNRFSGSKSGNT ASLTIS GLQAEDEAD YYCS SYAGS GIYVF GTGT KVTV L |
Nirsevimab | Whole mAb | G1 | Kappa | Preregistration | Active | QVQLVQSGAEVKKPGSSVMVSCQASGGLLEDYIINWVRQAPGQGPEWMGGIIPVLGTVHYGPKFQGRVTITADESTDTAYMELSSLRSEDTAMYYCATETALVVSETYLPHYFDNWGQGTLVTVSS | DIQMTQSPSSLSAAVGDRVTITCQASQDIVNYLNWYQQKPGKAPKLLIYVASNLETGVPSRFSGSGSGTDFSLTISSLQPEDVATYYCQQYDNLPLTFGGGTKVEIK | na | na | 5udc:HL:BC:EG/5udd:JP:KQ:LR:MS:OU:NT | null | 4jha:HL/4jhw:HL/6s3d:AB:CD:EF:HL | 2,018 | 2019 | RSV | AIMM Therapeutics;MedImmune | na | Respiratory syncytial virus infections | na | na | null | Q VQLVQ SGA EVK KPGS SVMVSCQ ASGGL LEDYI IN WVR QAPGQGPEWMGG IIPVLGTVHY GPKFQG RVTITA DESTD TAYMELS SLRSEDT AMYYCA TET ALVVSE TYLPHYFDNWGQG TLVTV SS | DIQMTQSPSS LSA AVGD RVTITCQ AS QDIVNYLNWYQ QKPGKAP KLLIYVA SNLETGVPSRFSGSGSGTD FSLTIS SLQ PEDVATYYCQQ YDNLP LTF GGGT KVEI K |
Nisevokitug | Whole mAb | G2 | Lambda | TBC | Active | QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGLWEVRALPSVYWGQGTLVTVSS | SYELTQPPSVSVAPGQTARITCGANDIGSKSVHWYQQKAGQAPVLVVSEDIIRPSGIPERISGSNSGNTATLTISRVEAGDEADYYCQVWDRDSDQYVFGTGTKVTVL | na | na | null | null | null | 2,022 | na | TGFB1/TGFB2 | TBC | TBC | TBC | TBC | TBC | null | Q VQLVQ SGA EVK KPGS SVKVSCK ASGGT FSSYAISWVR QAPGQGL EWMGGIIPIF GTANYAQKFQG RVTITA DESTS TAYMELS SLRSEDT AVYYC ARGL WEVRA LPS VYW GQG TLVTVS S | SYELTQPPS VSV APGQ TARITC GANDIGSK SVHWYQ QKAGQAP VLVVS ED II RPSGIPE RI SGSNSGN TATLTISRVE AGDE ADYYCQVWD RDSD QYVFG TGT KVTV L |
Nivatrotamab | Bispecific Mixed mAb and scFv | G1;na | Kappa;Kappa | Phase-I/II | Active | QVQLVESGPGVVQPGRSLRISCAVSGFSVTNYGVHWVRQPPGKGLEWLGVIWAGGITNYNSAFMSRLTISKDNSKNTVYLQMNSLRAEDTAMYYCASRGGHYGYALDYWGQGTLVTVSS | EIVMTQTPATLSVSAGERVTITCKASQSVSNDVTWYQQKPGQAPRLLIYSASNRYSGVPARFSGSGYGTEFTFTISSVQSEDFAVYFCQQDYSSFGQGTKLEIK | QVQLVQSGGGVVQPGRSLRLSCKASGYTFTRYTMHWVRQAPGKCLEWIGYINPSRGYTNYNQKFKDRFTISRDNSKNTAFLQMDSLRPEDTGVYFCARYYDDHYSLDYWGQGTPVTVSS | DIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQTPGKAPKRWIYDTSKLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSNPFTFGCGTKLQIT | None;None | None;None | None;None | 2,020 | 2021 | GD2;CD3E | Memorial Sloan-Kettering Cancer Center | na | Neuroblastoma | na | na | null | Q VQLVE SGPG VV QPGR SLRISCAV SGF SVTNYGVHWVR QPPGKGL EWLGVIWA GGITNYNSA FMSRLTIS KDNSKN TVYLQMNS LRAEDT AMYYCA SRGGHY GYALDY WGQG TLVTVS S | E IVMT QTPA TLSVS AGE RVTITCK ASQSVSND VTWYQ QKPGQAP RLLIYS ASNRYSGVP ARF SGSGYGT EFTFTISS VQSED FAVYFCQ QDYSSFGQG TKLEI K |
Nivolumab | Whole mAb | G4 | Kappa | Approved | Active | QVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSS | EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIK | na | na | 5ggq:HL/5wt9:HL/5ggr:HL:AB | null | null | 2,012 | 2013 | PDCD1 | Aduro BioTech;AIO Studien gGmbH;Australian and New Zealand Urogenital and Prostate Cancer Group;Barbara Ann Karmanos Cancer Institute;Bavarian Nordic;Big Ten Cancer Research Consortium;Bristol-Myers Squibb;Canadian Cancer Trials Group;Celleron Therapeutics;Clatterbridge Cancer Centre NHS Foundation Trust;Clovis Oncology;Curie Institute;Daiichi Sankyo Company;Dana-Farber Cancer Institute;Duke University Medical Center;Eisai Inc;Eli Lilly;Emory University;European Thoracic Oncology Platform;Exelixis;Frontier Science foundation;Grupo Espanol Multidisciplinar de Melanoma;H. Lee Moffitt Cancer Center and Research Institute;Hellenic Genitourinary Cancer Group;Hoosier Cancer Research Network;HOVON Foundation;Incyte Corporation;Intergroupe Francophone de Cancerologie Thoracique;Janssen Biotech;Janssen Research & Development;Kansai Medical University;Kyoto Breast Cancer Research Network;M. D. Anderson Cancer Center;Massachusetts General Hospital;Medarex;Nantes University Hospital;National Cancer Center (Tokyo);National Cancer Centre (Singapore);National Cancer Institute (USA);Nektar Therapeutics;Neon Therapeutics;Netherlands Cancer Institute;Northwestern University;Ono Pharmaceutical;Pharmacyclics;PrECOG;Seattle Genetics;Sidney Kimmel Cancer Center;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;Syneos Health;The University of Montreal Hospital Research Center;UNICANCER;University College London;University of Liverpool;University of Pittsburgh;University of Texas M. D. Anderson Cancer Center;Vanderbilt-Ingram Cancer Center;Zucero Therapeutics | Colorectal cancer;Gastric cancer;Head and neck cancer;Hodgkin's disease;Malignant melanoma;Non-small cell lung cancer;Renal cell carcinoma;Urogenital cancer;Liver cancer;Mesothelioma;Small cell lung cancer | Bladder cancer;Fallopian tube cancer;Glioblastoma;Multiple myeloma;Oesophageal cancer;Ovarian cancer;Peritoneal cancer;Non-Hodgkin's lymphoma;Acute myeloid leukaemia;Adrenocortical carcinoma;Biliary cancer;Brain metastases;Breast cancer;Bronchopulmonary dysplasia;Cancer;Cervical cancer;Cholangiocarcinoma;Chronic lymphocytic leukaemia;CNS cancer;Diffuse large B cell lymphoma;Follicular lymphoma;Genitourinary disorders;Leucoplakia;Liver metastases;Meningeal carcinomatosis;Myelodysplastic syndromes;Nasopharyngeal cancer;Oropharyngeal cancer;Pancreatic cancer;Penile cancer;Prostate cancer;Soft tissue sarcoma;Solid tumours;Testicular cancer;Thyroid cancer;Uterine cancer;Uveal melanoma;Haematological malignancies;Lymphoma;Rectal cancer;Glioma | Chronic myeloid leukaemia;Hepatitis C;Sepsis | Medarex UltiMAb Mouse | null | Q VQLVES GGG VV QPGR SLRLDC KASG ITFS NSG MHWVRQ APGKGL EWVAVIWY DGSK RYYAD SVKG RFTISR DNSKN TLFLQMN SLRAEDT AVYYCA TNDDYWGQ GTLVTVS S | E IVLTQ SPA TLSL SPGE RATLSCR ASQS VSS YLAWY QQKPGQAP RLLIYD ASNRATG I P ARF SGSGSGT DFTLTIS SLEPED FAVYYCQ QSSNWPRTFGQGT KVEI K |
Nofazinlimab | Whole mAb | G4 | Kappa | Phase-III | Active | QVQLVQSGAEVKKPGSSVKVSCKASGFTFTTYYISWVRQAPGQGLEYLGYINMGSGGTNYNEKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCAIIGYFDYWGQGTMVTVSS | DVVMTQSPLSLPVTLGQPASISCRSSQSLLDSDGGTYLYWFQQRPGQSPRRLIYLVSTLGSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQLTHWPYTFGQGTKLEIK | na | na | null | null | null | 2,021 | 2022 | PDCD1 | Cstone Pharmaceuticals | na | Solid tumours;Hepatocellular carcinoma | na | na | null | Q VQLVQ SGA EVK KPGS SVKVSCK ASGF TFTTYYISWVR QAPGQGL EYLGYINM GSGGTNYNEKFKG RVTITA DKSTS TAYMELS SLRSEDT AVYYCAIIGYF DYWGQG TMVTVS S | DV VMT QSPLSLP VT LGQPA SISCR SSQ SLL DSDGG TYLYWFQ QRPGQSPR RLIYLVST LGSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCMQLT HWPYTFGQGT KLEI K |
Nurulimab | Whole mAb | G1 | Kappa | Phase-I | Discontinued | EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK | na | na | null | 5xj3:AB:DE:GH:JK/5tru:HL:hl/6jc2:HL/6rp8:HL:hl/7elx:HL:hl | null | 2,019 | 2020 | CTLA4 | Biocad | na | na | Malignant melanoma | na | Likely to be an Ipilimumab Biosimilar | E VQLVES GGG VV QPGR SLRLSC AASGF TFSSYTMHWVRQ APGKGL EWVTFISY DGNNK YYAD SVKG RFTISR DNSKN TLYLQMN SLRAEDT AIYYCA RTGWLGPFDYWGQG TLVTV SS | E IVLTQ SPG TLSL SPGE RATLSCRA SQSVGS SYLAWYQ QKPGQAP RLLIYGAF SRATGIPDRFSGSGSGT DFTLTISR LEPED FAVYYCQ QYGSSPW TF GQGT KVEI K |
Obexelimab | Whole mAb | G1 | Kappa | Phase-III | Active | EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWGQGTLVTVSS | DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK | na | na | null | null | null | 2,018 | 2019 | CD19 | Xencor | na | Autoimmune disorders;Rheumatoid arthritis;Systemic lupus erythematosus | na | XmAb Antibody Engineering Technology | null | E VQLVES GGG LV KPGG SLKLSC AASGY TFTSYVMHWVR QAPGKGL EWIGYI NPYNDGTKYNE KF Q GRVTIS SDKS ISTAYMELS SLRSEDT AMYYC ARGT YYY G TRVFD YWGQG TLVTVS S | D IVMT QSPA TLSL SPGE RATLSCR SSKSL Q NVNGN TYLYWFQ QKPGQSP QLLIYRM SNLNSGVPDRFSGSGSGT EFTLTIS SLEPED FAVYYCM QHLEYP ITF GAGT KLEI K |
Obiltoxaximab | Whole mAb | G1 | Kappa | Approved | NFD | QVQLQQSGPELKKPGASVKVSCKDSGYAFSSSWMNWVRQAPGQGLEWIGRIYPGDGDTNYNGKFQGRVTITADKSSSTAYMELSSLRSEDTAVYFCARSGLLRYAMDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDIRNYLNWYQQKPGKAVKLLIYYTSRLLPGVPSRFSGSGSGTDYSLTISSQEQEDIGTYFCQQGNTLPWTFGQGTKVEIR | na | na | null | null | null | 2,015 | 2016 | Anthrax Protective Antigen | Elusys Therapeutics | Anthrax | na | na | na | null | QV QLQ QSGPELKKPGA SVKVSC KDSGY AFS SS W MNWVR QAPGQG LEWIGRI YPGDGDTNYNG KFQGRVTITA DKSSS TAYMELS SLRSEDT AVYFCA RSGL LRYAMD YWGQG TLVTVS S | DIQMTQSPSS LSA SVGD RVTITCR AS QDIRNYLNWYQ QKPGK AVKLLIYYT SRLLPGVPSRFSGSGSGTD YSLTI SSQEQEDI GTYFC QQGNTLPW TF GQGT KVEI R |
Obinutuzumab | Whole mAb | G1 | Kappa | Approved | Active | QVQLVQSGAEVKKPGSSVKVSCKASGYAFSYSWINWVRQAPGQGLEWMGRIFPGDGDTDYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNVFDGYWLVYWGQGTLVTVSS | DIVMTQTPLSLPVTPGEPASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLVSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPYTFGGGTKVEIK | na | na | 3pp3:HL:IK/3pp4:HL | 6y9a:HL | 6y97:HL | 2,008 | 2011 | MS4A1 | GLYCART Biotechnology;Biogen Idec;Chugai Pharmaceutical;Dana-Farber Cancer Institute;Genentech;Lymphoma Academic Research Organisation;Nippon Shinyaku;OHSU Knight Cancer Institute;Pharmacyclics;Polish Myeloma Consortium;Roche;Thomas Jefferson University;University of Heidelberg;University of Leeds | Chronic lymphocytic leukaemia;Follicular lymphoma;Non-Hodgkin's lymphoma | Diffuse large B cell lymphoma;CNS cancer;Graft-versus-host disease;Lupus nephritis;Mantle-cell lymphoma;Waldenstrom's macroglobulinaemia | Primary biliary cirrhosis | GlycoMAb Technology | Obinutuzumab is the new name for Afutuzumab (PL101) | Q VQLVQ SGA EVK KPGS SVKVSCK ASGY AFSYSWINWVR QAPGQG LEWMGRI FPGDGDTDYNGK FKGRVTITA DKSTS TAYMELSS LRSEDT AVYYCAR NVFDG YWLVYW GQG TLVTVS S | DI VMT QTPLSLPVTPGEPA SISCR SSK SLLH SNG ITYLYWYLQ KPGQSP QLLIYQM SNLVSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCA QNLELPY T FGGG TKVEI K |
Obrindatamab | Bispecific scFv with Domain Crossover | na;na | Kappa;Lambda | Phase-I | Discontinued | EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAYISSDSSAIYYADTVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCGRGRENIYYGSRLDYWGQGTTVTVSS | DIQLTQSPSFLSASVGDRVTITCKASQNVDTNVAWYQQKPGKAPKALIYSASYRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPFTFGQGTKLEIK | EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKDRFTISRDDSKNSLYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS | QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPWTPARFSGSLLGGKAALTITGAQAEDEADYYCALWYSNLWVFGGGTKLTVL | None;None | None;None | None;None | 2,020 | 2021 | CD276;CD3E | MacroGenics | na | na | Advanced or Metastatic solid tumours | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF TFSS F GMHWVRQ APGKG LEWVAYIS SDSS AIYYAD TVKG RFTISR DNAKNS LYLQMN SLRDEDT AVYYC GRGREN IYY GS RLDY WGQG TTVTVS S | DI QLT QSPS FLSA SVGD RVTITCK ASQNVDTN VAWYQ QKPGKAPK ALIYSASYRY SGVPSRFSGSGSGTD FTLTISS LQP EDFAT YYCQ QYNNYPF T FGQGT KLEI K |
Ocaratuzumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | EVQLVQSGAEVKKPGESLKISCKGSGRTFTSYNMHWVRQMPGKGLEWMGAIYPLTGDTSYNQKSKLQVTISADKSISTAYLQWSSLKASDTAMYYCARSTYVGGDWQFDVWGKGTTVTVSS | EIVLTQSPGTLSLSPGERATLSCRASSSVPYIHWYQQKPGQAPRLLIYATSALASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQWLSNPPTFGQGTKLEIK | na | na | null | null | null | 2,012 | 2013 | MS4A1 | Applied Molecular Evolution;MENTRIK Biotech | na | na | Follicular lymphoma;Non-Hodgkin's lymphoma;Rheumatoid arthritis | na | null | E VQLVQ SGA EVK KPGE SLKISC KGSGR TFTSYNMHWVRQ MPGKGL EWMGAIYP LTGDTSYNQKS KLQVTIS ADKS ISTAYLQWSS LKASDT AMYYCARSTYV GGD WQFDVW GKG TTVTVS S | E IVLTQ SPG TLSL SPGE RATLSCR ASSSVP YIHWYQ QKPGQAP RLLIYAT SALASGIPDRFSGSGSGT DFTLTISR LEPE D FAVYYCQ QW LSNPPTFGQGT KLEI K |
Ociperlimab | Whole mAb | G1 | Kappa | Phase-III | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYYMYWVRQAPGKGLEWVAYITKGGGSTYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARQTNYDFTMDYWGQGTLVTVSS | EIVMTQSPATLSVSPGERATLSCKASQDVGTSVAWYQQKPGQAPRLLIYWASARHTGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYSSYPLTFGGGTKVEIK | na | na | null | null | null | 2,020 | 2021 | TIGIT | BeiGene | na | Non-small cell lung cancer; Cervical cancer; Small-cell lung cancer; Squamous cell cancer; Solid tumours | na | na | (June '22: Corrected CDRH1 sequence) | E VQLVES GGG LV QPGG SLRLSCA ASGF TF SD YYMYWVRQ APGKG LEWVAYIT KGGGST Y YPDSVK GRFTISR DNAKN TLYLQMN SLRAEDT AVYYCAR QTNY DFTMDY WGQG TLVTVS S | E IVMT QSPA TLSV SPGE RATLSCKA SQDVGT SVAWYQ QKPGQAP RLLIYWAS ARHTGIP ARFS GSGSGT EFTLTISS LQSED FAVYYCQ QYSSYP LTF GGG TKVEI K |
Ocrelizumab | Whole mAb | G1 | Kappa | Approved | NFD | EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYNMHWVRQAPGKGLEWVGAIYPGNGDTSYNQKFKGRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARVVYYSNSYWYFDVWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASSSVSYMHWYQQKPGKAPKPLIYAPSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSFNPPTFGQGTKVEIK | na | na | null | null | 4k7p:YX | 2,005 | 2006 | MS4A1 | Biogen;Biogen Idec;Chugai Pharmaceutical;Genentech;Roche | Multiple sclerosis | na | Eye disorders;Haematological malignancies;Lupus nephritis;Rheumatoid arthritis;Systemic lupus erythematosus | na | null | E VQLVES GGG LV QPGG SLRLSC AASGY TFTSYNMHWVRQ APGKG LEWVGAIY PGNGDTSYNQKFK GRFTISVD KSKN TLYLQMNSL RAEDT AVYYCARVVYY SNS YWYFDV WGQG TLVTVS S | DI QMT QSPSS LSA SVGD RVTITCR ASSS VSYMHWYQ QKPGKAPKP LIY APSNLASGVPS R FSGSGSGT DFTLTISS LQPEDF ATYYCQQW SFNPPTFGQGT KVEI K |
Odesivimab | Whole mAb | G1 | Kappa | Approved | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDMHWVRQATGKGLEWVSAIGTAGDTYYPGSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARTWFGELYFDYWGQGTLVTVSS | DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTEFTLTITSLQAEDVAVYYCQQYYSSPLTFGGGTKVEIK | na | na | null | null | null | 2,019 | 2020 | Zaire Ebolavirus GP | Regeneron Pharmaceuticals | Ebola virus infections | na | na | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF TFSS YD MHWVRQ ATGKGL EWVSAIG TAGDTYYPGS VKGRFTIS RENAKN SLYLQMNS LRAGD TAVYYCA RTWFG ELYFD YWGQG TLVTV SS | D IVMT QSPDS LAVS LGE RATINC KSSQ SVLYS SNNK NYLAWYQ QKPGQPP KLLIYWAS TRESGVPDRFSGSGSGT EFTLTITS LQAED VAVYYCQQ YYSSPL TF GGG TKVEI K |
Odronextamab | Bispecific mAb | G4;G4 | Kappa;Kappa | Phase-III | Active | EVQLVESGGGLVQPGRSLRLSCVASGFTFNDYAMHWVRQAPGKGLEWVSVISWNSDSIGYADSVKGRFTISRDNAKNSLYLQMHSLRAEDTALYYCAKDNHYGSGSYYYYQYGMDVWGQGTTVTVSS | EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQHYINWPLTFGGGTKVEIK | EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYTMHWVRQAPGKGLEWVSGISWNSGSIGYADSVKGRFTISRDNAKKSLYLQMNSLRAEDTALYYCAKDNSGYGHYYYGMDVWGQGTTVTVAS | EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQHYINWPLTFGGGTKVEIK | None;None | None;None | None;None | 2,019 | 2020 | MS4A1;CD3E | Regeneron Pharmaceuticals | na | Follicular lymphoma;B-cell lymphoma;Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma;Precursor B-cell lymphoblastic leukaemia-lymphoma | na | na | null | E VQLVES GGG LV QPGR SLRLSCVA SGF TF NDY AMHWVRQ APGKGL EWVSVISW NSDSIGYADSVKG RFTISR DNAKNS LYLQMHSL RAEDT ALYYCA KDNHYGSGS YYYYQY GM DVW GQG TTVTVS S | E IVMT QSPA TLSV SPGE RATLSCR ASQSVSSN LAWYQ QKPGQAP RLLIYG ASTRATGIP ARFS GSGSGT EFTLTISS LQSED FAVYYCQHYI NWPL T FGGG TKVEI K |
Ofatumumab | Whole mAb | G1 | Kappa | Approved | Active | EVQLVESGGGLVQPGRSLRLSCAASGFTFNDYAMHWVRQAPGKGLEWVSTISWNSGSIGYADSVKGRFTISRDNAKKSLYLQMNSLRAEDTALYYCAKDIQYGNYYYGMDVWGQGTTVTVSS | EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTRLEIK | na | na | 3giz:HL/6y92:HL:CD | null | null | 2,005 | 2006 | MS4A1 | Genmab;GlaxoSmithKline;Mundipharma International;National Cancer Centre (Singapore);Novartis;Roswell Park Cancer Institute;University Health Network | Chronic lymphocytic leukaemia | B-cell lymphoma;Diffuse large B cell lymphoma;Follicular lymphoma;Multiple sclerosis;Marginal zone B-cell lymphoma;Precursor cell lymphoblastic leukaemia-lymphoma | Neuromyelitis optica;Pemphigus vulgaris;Rheumatoid arthritis;Waldenstrom's macroglobulinaemia | Medarex HuMAb Mouse | null | E VQLVES GGG LV QPGR SLRLSC AASGF TF NDY AMHWVRQ APGKGL EWVSTISW NSGSI GYA DSVKG RFTIS RDNAKK SLYLQM NSLRAEDT ALYYCA KDIQYGN YYYGMDV WGQG TTVTVS S | E IVLTQ SPA TLSL SPGE RATLSCR ASQS VSSY LAWY QQKPGQAP RLLIYD ASNRATGIP ARF SGSGSGTD FTLTIS SLEPE D FAVYYCQ QRSNWP ITF GQGT RLEI K |
Ogalvibart | Whole mAb | G1 | Kappa | Phase-II/III | Active | QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVIPFDGRNKYYADSVTGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASSSGYLFHSDYWGQGTLVTVSS | DIQMTQSPSTLSASVGDRVTITCRASQSISNWLAWFQQKPGKAPKLLIYEASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYPWTFGQGTKVEIK | na | na | 7k8r:HL/7k8z:HL:MN | null | null | 2,022 | na | SARS-CoV-2 Spike RBD | National Institute of Allergy and Infectious Diseases;Rockefeller University;Xencor | na | COVID-19 | na | na | null | Q VQLVES GGG VV QPGR SLRLSC AASGF TFSSYAMHWVRQ APGKG LEWVAVIP FDGRNK YYA DSVT GRFTISR DNSKN TLYLQMN SLRAEDT AVYYCA SSSG YLFH SDYWGQG TLVTVS S | DIQMTQSPS TLSAS VGD RVTITCR ASQS ISNWLAWFQ QKPGKAP KLLIYE ASSLESGVPS R FSGSGSGT EFTLTIS SLQPDD FAT YYCQ QYNSYPW T FGQGT KVEI K |